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Abstract: GABA(A) receptors are ligand-gated ion channels consisting of five subunits from eight
subfamilies, each assembled in four hydrophobic transmembrane domains. This pentameric structure
not only allows different receptor binding sites, but also various types of ligands, such as orthosteric
agonists and antagonists, positive and negative allosteric modulators, as well as second-order
modulators and non-competitive channel blockers. A fact, that is also displayed by the variety of
chemical structures found for both, synthetic as well as nature-derived GABA(A)-receptor modulators.
This review covers the literature for natural GABA(A)-receptor modulators until the end of 2017 and
discusses their structure-activity relationship.
Keywords: γ-aminobutyric acid; natural product; plant origin; benzodiazepine binding site;
anxiolytic; sedative; anesthetic; anticonvulsant
1. Introduction
GABA (γ-aminobutyric acid) type A receptors are members of the ligand-gated ion-channel
superfamily, consisting of four hydrophobic transmembrane domains (TM1–TM4) [1]. Around the
pore, five subunits form eight subunit subfamilies (α, β, γ, δ, ε, θ, pi and $) assemble to form a
heteropentameric chloride (Cl−)-permeable channel [2]. Despite the extensive heterogeneity of the
GABA(A) receptor subunits, most GABA(A) receptors expressed in the brain consist of two α subunits,
two β subunits and one γ subunit [1]. Each receptor subunit also contains a large intracellular domain
between TM3 and TM4, which is the site for various protein interactions as well as for various
post-translational modifications that modulate receptor activity [1]. Its endogenous ligand is GABA,
the major inhibitory neurotransmitter in the central nervous system, which upon activation selectively
conducts Cl− through its pore, resulting in hyperpolarization of the neuron [3]. This causes an
inhibitory effect on the neurotransmission by diminishing the chance of a successful action potential
occurring [3]. The active site of the GABA(A) receptor is the binding site for GABA and several drugs
such as muscimol, gaboxadol and bicuculline [3]. Additionally, the receptor contains several different
allosteric binding sites, which modulate the activity of the receptor indirectly and are the targets of
various other drugs, such as benzodiazepines, barbiturates, ethanol, picrotoxin, general anaesthetics
and neuroactive steroids [4–7].
Due to the structural heterogeneity of GABA(A) receptors and the number of binding sites, natural
(and synthetic) compounds with a variety of chemical structures were discovered to possess GABA(A)
receptor modulating properties and depending on the mode of action, the affected binding site and
the compounds’ affinity, to exhibit diverse pharmacological effects. Investigation of these effects was
accomplished using different in vitro and in vivo models. Of the in vitro studies, about half of the
reports result from radioligand binding assays, where compounds were tested for their ability to
displace a ligand from its respective binding site. Possible binding sites to be studied with these
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assays are the GABA/muscimol-, the benzodiazepine- and the tert-butylbicyclophosphorothionate
(TBPS)/picrotoxin-binding site [8]. Other in vitro models to determine GABAergic activity are
electrophysiological studies, such as voltage clamp techniques. In these systems, compounds can
be investigated for their stimulation or inhibition of chloride currents on recombinant GABA(A)
receptors expressed in different cell types, allowing to measure receptors composed of different
subunits. Additional in vivo studies helped to understand the correlation of subtype modulation and
the respective pharmacological effects, such as anxiolytic, sedative and anticonvulsive properties.
Several animal models are described to assess anxiolytic potential, which evaluate either
conditioned or unconditioned responses [9]. Conditioned responses are measured in the Vogel conflict
(VC) and the four-plate-test (FP), where mild electroshocks are used to punish drinking or exploratory
behavior, respectively [9,10]. Evaluation of unconditioned responses is accomplished using the elevated
plus maze (EPM), the open field (OF), the holeboard (HB) or the light/dark exploration test (LD),
where the aversion of rodents to elevated, open or brightly lit areas is determined [10]. Other animal
models to measure effects on anxiety and/or stress are the marble burying test (MB), the forced swim
test (FS), the tail suspension test (TS) and stress-induced hyperthermia (SIH) [10,11]. The open field
test can also be used to assess locomotor activity (LMA) of the animals, determining the number of
crossings, rears and grooms as well as the total distance travelled [12]. Other models to measure
sedative/hypnotic effects are pentobarbital-induced sleeping (PIS) or ethyl ether-induced sleeping
(EIS), where an increase in sleep latency and sleep duration are measured. To assess anticonvulsant
properties, animals are treated with either electroshocks (MES), pentetrazol (PTZ) or picrotoxin (PTX) in
order to provoke seizures [13]. Parameters to be measured are the number and intensity of convulsions,
seizure latency and time to death. Additional animal models discussed in this review are the rotarod
(RR) and the horizontal wire test (HW), where compounds are tested for their myorelaxant properties
as well as the tail-flick (TF) response and the tail immersion test (TI), which are used to measure
analgesic effects [14–17].
Meanwhile, several pharmacological effects can be attributed to the modulation of specific
α-subunits [2,18]. Sedative and hypnotic properties, for example, are mediated via GABA(A)
receptors containing α1-subunits, whereas positive modulation of GABA(A) receptors with α2 and/or
α3-subunits displays anxiolytic effects. Moreover, α5-subunits play a role in learning and memory.
Benzodiazepines, common therapeuticals for the treatment of anxiety, insomnia and convulsions,
are known to act on α1, α2, α3 and α5 subunits, which is the reason for some of their side-effects,
such as muscle relaxation or anterograde amnesia [18,19]. Other disadvantages are the development
of tolerance and dependence. Therefore, the discovery of new and safer medicines, with, e.g., strong
anxiolytic but weak sedative potential, is urgently warranted. In recent decades, various reports have
been made on natural products with GABAergic activity and, as already mentioned, different kinds
of methods have been used to describe the effects. Hence, the aim of this review was to collect the
existing data and make the obtained results as comparable as possible, thus facilitating the discussion
of structure activity relationships.
2. Method
A literature search was carried out using the Web of Science citation indexing service and the terms
“GABA receptor” and “gamma-aminobutyric acid receptor” in combination with the words “natural”,
“naturally occurring” or “plant-derived”, resulting in 795 publications. Additionally, the terms “GABA
receptor” and “gamma-aminobutyric acid receptor” were searched alone and the results were reduced
to the field of plant science, giving 244 hits. The publications were reviewed by title, abstract and text
and reduced to those dealing with GABA type A receptors. Furthermore, studies of extracts (without
identifying active single molecules) were excluded. Data of the remaining publications was collected
and categorized by the pharmacological methods used (voltage clamp techniques, radioligand binding
assays and in vivo studies) and the chemical structures of the active molecules. Chemical structures
were divided into compound classes (alkaloids, alkanes, phenols and terpenes) and, depending on the
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number compounds, into several subclasses, thereby defining the structure of this review. Compound
names (mostly trivial names) and configurations were taken “as is” from the original publications and
species names of the natural sources used in the studies were checked using “The Plant List” or “Index
Fungorum”, respectively [20,21]. If not specified otherwise, doses administered in the in vivo studies
were intraperitoneal and animals tested were either mice or rats. Diazepam was generally used as
reference compound.
The data discussed in this review is additionally summarized in four tables at the end of this
review. Data from electrophysiological recordings is divided into antagonists (Table 1) and agonists
(Table 2). Here, compound number, source, assay and expressed subtype combination are given,
as well as EC50 values and maximal stimulation for agonists and IC50 values and percent inhibition for
antagonist, respectively. If results of different receptor subtypes were available, those measured with
α1β2γ2 are presented. If no maximal stimulation was given in the original publications, the highest
obtained value and concentration is presented instead. Table 3 shows data from radioligand binding
assays. As above, compound number, source, IC50 values and maximal stimulation are given, as well as
Ki values and the applied radioligand. Compounds are ordered by the studied binding site. In Table 4,
data from the in vivo studies is depicted. Here, either the lowest active dose is presented and, if no
doses are given, + or − is shown if significant results were (+) or were not observed (−). In the tables
as well as in the main text, only results with a p value below 5% (p < 0.05) were considered.
3. Natural GABA(A) Receptor Modulators
3.1. Alkaloids
A total of 19 alkaloids (including four protoalkaloids) have been reported to possess
GABA(A)-modulating activity (Figure 1).
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Figure 1. Chemical structures of alkaloids with reported GABA(A)-receptor modulating activity. 
Alali et al. isolated (−)-colchicine (1), (−)-androbiphenyline (2) and (−)-cornigerine (3) along with 
six other colchicinoids from Colchicum brachyphyllum, which meanwhile is classified as Colchicum 
szovitsii ssp. brachyphyllum [22]. Of the nine isolated compounds, 2 and 3 acted as weak partial 
agonists in a radioligand binding assay using [35S]TBPS and [3H]flunitrazepam. The two compounds 
exhibited about 25% of the stimulation of 10 µM allopregnanolone, while (−)-colchicine showed no 
activity. This finding is in accordance with a previous study of Bueno et al., which identified (−)-
colchicine as a competitive antagonist of GABA, decreasing the GABAergic responses to 40% of the 
control level [23].  
Figure 1. Chemical structures of alkaloi s it r rted GABA(A)-receptor modulating activity.
Alali et al. isolated (−)-colchicine (1), (−)-androbiphenyline (2) and (−)-cornigerine (3)
along with six other colchicinoids from Colchicum brachyphyllum, which meanwhile is classified as
Colchicum szovitsii ssp. brachyphyllum [22]. Of the nine isolated compounds, 2 and 3 acted as weak
partial agonists in a radioligand binding assay using [35S]TBPS and [3H]flunitrazepam. The two
compounds exhibited about 25% of the stimulation of 10 µM allopregnanolone, while (−)-colchicine
showed no activity. This finding is in acc rdance with a previous study of Bueno et al., which identified
(−)-colchicine as a competitive antagonist of GABA, decreasing the GABAergic responses to 40% of
the control level [23].
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Another protoalkaloid with reported GABAergic activity is leonurine (4) from Leonurus japonicus,
an East Asian herbal remedy for the treatment of anxiety, depression, nervousness, and insomnia [24].
In a radioligand assay with [3H]gabazine and [3H]flumazenil the compound showed IC50 values of
15 µg/mL and 123 µg/mL, respectively.
Piperidine-alkaloids piperine (5) and piperanine (6) were investigated in Xenopus laevis oocytes by
Zaugg et al. [25]. At a concentration of 100 µM and in the presence of GABA, the compounds induced
potentiation of chloride currents of 226% and 138%, respectively. The maximum stimulation observed
was 302% (5) and 187% (6), and EC50 values were calculated as 52 and 56 µM, respectively. As the
effects were not antagonized by flumazenil, the observed allosteric modulation must be independent
from the benzodiazepine binding site.
Halbsguth et al. isolated four protoberberine type 1 and five protoberberine type 2 alkaloids
(7–11) from the rhizomes of Corydalis cava [26]. While type 1 alkaloids elicited no effect in a radioligand
assay with [3H]BMC (bicuculline methochloride), type 2 alkaloids enhanced BMC binding by 21–49%
at concentrations of 0.1 µM (7, 8,11) and 0.01 µM (9,10), indicating the necessary saturation of both
heterocycles. Scoulerine (10) was additionally investigated on the increase of Muscimol-Alexa binding,
increasing the amount of hindered mobility of the receptor ligand complex comparable to midazolam.
In vivo studies on tetrahydropalmatine (11), which was isolated from Corydalis yanshuo, showed an
increased number of open arm entries and time spent in the open arms at doses from 0.5 to 10 mg/kg
p.o. In the EPM and a decrease of time spent in open arms and closed arm entries at 30 and 50 mg/kg
p.o. [27]. At a dose of 50 mg/kg p.o. The compound also caused a decrease in head dips in the
holeboard test and led to performance deficits in the horizontal wire test.
Farzin et Mansouri investigated the antidepressant-like effect of β-carbolines harmane (12),
harmine (13) and norharmane (14) in the forced swim test on mice [28]. Harmane and harmine
dose-dependently reduced the immobility time from 5 to 15 mg/kg, while norharmane was already
effective at a dose of 2.5 mg/kg. Flumazenil (5 mg/kg) completely antagonized the effect, suggesting
the antidepressant effect to be triggered via the benzodiazepine binding site.
Another β-carboline with GABAergic activity, annomontine (15), was isolated from Annona
purpurea [29]. In the EPM test, the compound increased the time spent in the open arms and
the open arm entries at 10 and 30 mg/kg, but not the total arm entries. Flumazenil at a dose of
3 mg/kg antagonized the effect and thus confirmed the above-mentioned effect of β-carbolines on the
benzodiazepine binding site. However, in the open field test, annomontine showed no differences on
the number of lines crossed and the number of rearings compared to vehicle and diazepam. Neither did
the investigation of locomotor activity in the rotarod test and the pentobarbital-induced sleeping test
show any significant results.
Eder et al. reported the isolation of three pyridoacridine alkaloids, kuanoniamine C (16), D (17)
and N-desacetylkuanoniamine (18) from a Micronesian sponge of the genus Oceanapia [30]. In a
radioligand assay all three compounds showed moderate affinity to the benzodiazepine binding site,
inhibiting the binding of [3H]diazepam by 30 to 39% at a test concentration of 25 µM each.
The last alkaloid to be discussed in this review is songorine (19), a diterpene alkaloid which was
isolated from Aconitum leucostomum and found to be a non-competitive GABA(A) receptor antagonist,
with an IC50 value of 19.6 µM [31]. Additional radioligand studies using [3H]muscimol resulted in an
IC50 value of 7.06 µM and a Kd value of 6.31 nM. Nesterova et al. investigated the anxiolytic effect
of songorine (isolated from Aconitum barbatum) using the Vogel conflict test [32]. The compound at
a dose of 0.25 mg/kg intragastrically led to an increase in punished drinks without producing any
sedative effect.
Regarding the subtype specifity of the presented alkaloids, only β-carbolines (12–14) and
picroacridine alkaloids (15–18) can be attributed to a specific binding site, which in this case is the
benzodiazepine binding site. For piperidine alkaloids (5,6) and protoberberine alkaloids (7–11) this
binding site can at least be excluded, as can the the GABA/muscimol binding site for songorine
(19). The three colchicinoids (1–3) seem to exhibit unspecific binding with no (1) or weak (2 and 3)
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stimulation on both the benzodiazepine as well as the TBPS/bicuculline binding site. The more
interesting fact is that colchicine (1) acts as receptor antagonist, whereas androbiphenyline (2) and
cornigerine (3) are both partial agonists. Also, the fourth protoalkaloid, leonurine (4), shows binding
to different sites, with weak affinities to both, the GABA/muscimol and the benzodiazepine binding
site. Another finding is that only protoberberine type 2 alkaloids were able to modulate GABA(A)
receptors, whereas unsaturated type 1 alkaloids exhibited no effects.
3.2. Alkanes
In this section, 14 compounds will be described, of which twelve belong to the class of
polyacetylenes (Figure 2).
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The first compound, 1-octen-3-ol (20), was part of a study on the GABA(A) receptor modulation
of odor subst nces, which will be described in th section on terpenes [33]. Anyway, at a concentration
of 300 µM and 1 µM GABA 1-octen-3-ol exhibited a stimulation of 295 ± 50%.
The next compound, N-[(2S,3R,4E,6E)-1,3-dihydroxyhenicosa-4,6-dien-2-yl]tridecanamide (21),
is a ceramide, isolated from the Red Sea soft coral Sarcophytum auritum [34]. The compound was
reported to increase the time spent in the open arms in the EPM test and the time spent in the light are
in the light/dark test as well as the time to death after injection of pentylenetetrazol (PTZ). All actions
were antagonized by bicuculline (0.1 mg/kg), proving the effects to be mediated via a GABAergic
pathway. However, no information is given on the doses of 21 used in the different assays.
Oenanthotoxin (22) and dihydrooenanthotoxin (23), two polyacetylenes isolated form Oenanthe
fistulosa exhibited s rong inhibitory effects on GABA(A) receptors, with IC50 value of 0.835 µM
and 1.29 µM, respectively [35]. The authors conclude that this block of GABAergi responses is the
molecular rationale for the sympto s of poisoning from water-dropwort (Oenanthe crocata) and a
possible explanation for the facial muscular contractions, also known as risus sardonicus. A follow-up
study on the mechanisms of action of oenanthotoxin found the compound to allosterically modulate
GABA-binding and non-competitively block the ion channel at the same time, nearby abolishing
receptor desensitization [36].
Uwai et al. isolated five polyacetylenes, cicutoxin (24), isocicutoxin (25), virol A (26), B (27) and
C (28) from ater hemlock (Cicuta virosa) [37]. A radi ligand binding study using [3H]EBOB resulted in
IC50 values of 0.541 µM (24), 2.01 µM (25), 1.15 µM (26), 6.01 µM (27) and 7.87 µM (28). Further studies
with semisynthetic derivatives of the compounds revealed that both, t ter inal as well as the allylic
hydroxy-group are both important for the toxicity of the compounds.
In a study on falcarindiol (29) isolated from Oenanthe crocata, the compound was found to potently
modulate GABAergic currents at low micromolar concentrations [38]. A finding that was approved
Molecules 2018, 23, 1512 6 of 44
by a follow-up study by Czyzewska et al., who isolated falcarindiol along with falcarinol (30) from
Bunium bulbocastanum [39]. Both compounds were found to enhance GABA-induced ion currents
at low micromolar concentrations (1 µM for falcarindiol and 0.1 µM for falcarinol), but rather block
GABAergic activity at higher concentrations. The authors assume that the low-dose effect is the reason
for the sedative but not convulsive effect in animals, while the higher concentrations in herbivorous
insects act insecticidal.
The last three polyacetylenes with reported GABA(A)-modulating activity were isolated from
Cussonia zimmermannii and named MS-1 (31), MS-2 (32) and MS-4 (33) [40]. The three compounds
showed a stimulation of chloride currents from 110 to 440% with EC50 values ranging from 0.6 to 3.5 µM.
Of the 14 compounds discussed in this section, twelve belong to the class of polyacetylenes
(22–33), a compound class with interesting GABAergic activities. Altogether, they show efficacies
and/or affinities in the low micromolar range but differ strongly in terms of toxicity. According to
Uwai et al. The toxicity is caused by two structural features, the allylic and the terminal hydroxy-group,
which are both present in the five (most) toxic natural compounds of his study (24–28). Regarding the
data of the other reported polyacetylenes, it can further be concluded that the terminal hydroxy-group
is more important for the toxicity, as both oenanthotoxins (22,23) lack the allylic hydroxy-group but
are strongly poisonous. In contrast, falcarinol (30) and falcarindiol (29), which have an allylic but no
terminal hydroxy-group, show reduced toxicity. The last three polyacetylenes (31–33) have neither of
the two “toxic features”, and are also not reported to exhibit inhibitory activity, which is in accordance
with this theory. However, as MS-4 (33) has a terminal acetyloxy-group, it would be interesting to
study if hydrolisation led to GABA(A) receptor antagonism.
3.3. Phenols
3.3.1. Flavones
Most natural products with GABAergic activity have been reported from the class of flavones,
with 29 compounds isolated from Scutellaria baicalensis alone (Figure 3) [41,42].
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A radioligand binding assay using [3H]flunitrazepam revealed sub-micromolar Ki or IC50 values
for eleven of the isolated compounds (36–38,40,41,43,45,47–50). Compound 48 even showed affinity to
the benzodiazepine site at a nanomolar level (6.1 ± 0.1 nM), which was similar to that of diazepam
(6.4 ± 0.2 nM). Due to the number of structurally very similar compounds tested in the two studies,
some findings regarding the structure-activity relationship could be drawn:
• Hydroxylation in position 5 and 7 or in position 6 leads to increased receptor affinity.
• Methoxylation in position 6 or 8 also raises affinity of the compounds, even more when occurring
in both positions.
• The affinity furthermore increases by hydroxylation in position 2’, while methoxylation in the
same position leads to a loss of affinity.
Wang et al. additionally tested four flavanones, which altogether showed a much lower activity
than the respective flavones and, except for 87 (see next subsection), produced no considerable effect.
The major constituents of Scutellaria baicalensis were also part of other in vitro and in vivo studies.
Baicalein (54) and its glucuronide baicalin (55), for example, were tested for their anxiolytic potential
in the Vogel conflict test, where both compounds were found to increase the number of accepted
shocks at doses of 10 mg/kg [43]. Baicalin was also found to increase number of open arm entries
and time spent in the open arms in an EPM test after central (i.c.v.) application of 5.4 and 54 ng of the
compound [44]. At the same doses baicalein also increased ethyl ether-induced sleeping time but had
no effect on PTZ-induced seizures. Thus, the authors concluded that the anxiolytic-like and sedative
effects are mediated through GABA(A) receptors, but not via the benzodiazepine binding site. In a
study on the sleep-wake regulation of baicalin, the compound at doses of 42.7 and 85.3 ng led to a
decrease of slow wave sleep during the first 2 h in the light period and to an increase of slow wave
sleep of hours 8 to 12 in the dark period [45]. In the latter period, a dose of 85.3 ng also caused an
increase of rapid eye movement.
Oroxylin A (56), was tested for its effect on chloride currents in single cortical neurons and thereby
found to allosterically inhibit GABA-mediated receptor modulation [46], thus explaining the outcome
of an earlier in vivo study by Huen et al., where the compound did not show any significant results
but antagonizing the effects provoked by diazepam [47]. Interestingly, oroxylin A only differs from
baicalein by the presence of a methoxy-group in position 6.
Wogonin (46) was investigated on the potentiation of GABA-induced chloride currents, where it
exhibited a stimulation of 57% at a concentration of 30 µM in the presence of 1 µM GABA [48].
The calculated EC50 value was 3 µM. In the same study, wogonin showed an increase in head dips
and time spent head dipping in the holeboard test, as well as an increase in total arm entries and
open arm entries at the EPM test. The effects were observed at doses of 7.5, 15 and 30 mg/kg p.o. No
sedative or myorelaxant effects were observed in the locomotor activity test or the horizontal wire
test at doses up to 30 mg/kg p.o. Neither did intraperitoneal injection of 0.2 to 10 mg/kg lead to a
decrease in locomotor activity in a study on the anticonvulsant effect [49]. In this study, wogonin
reduced the intensity of maximal electroshock (MES)-induced seizures and PTZ (70 mg/kg)-induced
seizures at doses of 5 and 10 mg/kg. The higher doses also reduced the intensity seizures induced by
100 mg/kg PTZ.
The last flavone from Scutellaria baicalensis to be discussed is chrysin (45), though the compound
has been the target of earlier studies, where it was isolated from Passiflora caerulea [50–52]. Medina et al.
found the compound to be anticonvulsive, when applied i.c.v., but not when applied i.p. [50].
Wolfman et al. observed an increase in locomotor activity at doses from 0.6 to 1 mg/kg and an
increase of open arm entries and time spent in the open arms at a dose of 1 mg/kg, an effect that
was blocked by flumazenil [51]. The horizontal wire test showed a decreased percentage of animals
grasping the horizontal wire, while in the holeboard test an increase in time spent head-dipping at
3 mg/kg was observed, but no sedative effects at doses of 3 and 6 mg/kg. Zhai et al. reported a
decrease in tail withdrawal latencies after oral administration of 25, 50, 75 and 100 mg/kg chrysin in the
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tail immersion test [52]. As the effect was antagonised by flumazenil (0.75 and 1 mg/kg), bicuculline
(2 and 4 mg/kg) and picrotoxin (1 and 2 mg/kg) the authors conclude that the hyperalgesic effect is
associated with GABA(A) receptors. A study on the effect of chrysin and other flavones on memory
tasks showed by Salgueiro et al. did not reveal significant results for any of the tested compounds [53].
An in vitro study of chrysin on GABA-induced ion currents showed a slight inhibition (9.7% at 10 µM),
which reached its maximum (12.1%) at 30 µM [54].
In the same study, apigenin (63), quercetin (73) and morin (74) were identified as GABA inhibitors,
with maximal inhibitions of 50.6, 84.5 and 38.4%, respectively (Figure 4). Similar results for apigenin
were obtained by Avallone et al., who tested inhibition of chloride currents in cerebellar granule cells and
found the effect to be antagonized by flumazenil [55]. Campbell et al. and Kavvadias et al. described
this effect to be allosterically mediated and reported IC50 values of 8 and 6.9 µM, respectively [56,57].
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Due to its high abundance in the plant kingdom, apigenin was subject of various studies.
Viola et al. were testing the affinity to the benzodiazepine binding site using [3H]flunitrazepam
and determined a Ki value of 4 µM [58], while other studies were using [3H]flumazenil and calculated
IC50 values of 10 to 30 µM and a Ki value of 9 µM [57,59,60]. Viola et al. also tested the anxiolytic-like
behaviour in th EPM test and found an increased per entage of op n arm ntries and time spent in the
open arms but no differences in total arm entries at a dose of 3 mg/kg, while sedative effects were only
observed at doses of 30 and 100 mg/kg, respectively [58]. The sedative effects of apigenin at higher
doses (25 and 50 mg/kg) were confirmed by Avallone et al. but no anxiolytic-like effects in the EPM test
were noticed at doses of 0.5 to 10 mg/kg [55]. Apigenin also decreased the latency of picrotoxin-induced
seizures at 25 and 50 mg/kg, but had no effect on death rate and death latency. Neither did the
compound exhibit myorelaxant activity at a dose of 50 mg/kg. Gazola et al. investigated the edative
effect of apigenin isolated from Passiflora quadrangularis and measured an increase of sleep duration at
a dose of 0.6 mg/kg p.o. [61].
Another very common flavonoid with GABA-inhibiting properties is luteolin (64), which was
found to reduce stimulation of chloride currents to 66% of the control level at a concentration of
50 µM [62]. The IC50 valu was calculated with 6.62 µM.
Wasowski et al. isolated 6-methylapigenin (65) from Valeria a wallichii (now classified as Valeriana
jatamansi) and subjected the compound to a radioligand assay using [35S]TBPS [63]. The obtained
Ki value was 0.50 µM. In a follow-up study 6-methylapigenin was tested in the EPM test, where it
increased the percentage of open arm entries and time spent in the open arms at a dose of 1 mg/kg [64].
The compound additionally potentiated the sleep-enhancing properties of hesperidin, which was also
part of this study and will discussed later in this review.
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Hispidulin (66) and cirsimaritin (67) were isolated from Salvia officinalis and studied for
their affinity to the benzodiazepine binding site using [3H]flumazenil [65]. Even though both
compounds only differ by methylation of the 7-hydroxy-group their IC50 values vary strongly with
1.3 µM calculated for hispidulin and 350 µM for cirsimaritin. Hispidulin was further subjected to
electrophysiological studies in Xenopus laevis oocytes showing a maximal potentiation of 47% at
a concentration of 10 µM [57]. The authors additionally investigated the effect of hispidulin on
Mongolian gerbils. After seven days of treatment with 10 mg/kg p.o. per day milder seizures were
observed and the number of animals suffering from seizures was significantly reduced. Salah et al.
isolated hispidulin together with cirsilineol (68) from Artemisia herba-alba and found IC50 values of 8
and 100 µM in a radioligand binding assay with [3H]flumazenil [66].
Cirsiliol (69), a derivative of cirsilineol, was isolated by Viola et al. from Salvia guaranitica, which is
meanwhile classified as Salvia coerulea [67]. The compound was measured against [3H]zolpidem (Ki of
20 µM) and [3H]flunitrazepam (Ki value of 200 µM) and investigated in the pentobarbital-induced
sleeping test, where it showed hypnotic effects at doses from 2 to 10 mg/kg. Moreover, cirsiliol showed
produced no myorelaxant or anticonvulsant effects at doses of 30 and 10 mg/kg, respectively.
Shen et al. isolated dinatin (70) and skrofulein (71) from Artemisia herba-alba and tested the
compounds in a radioligand assay using [methyl-3H]diazepam and obtained IC50 values of 1.3 and
22.7 µM, respectively [68].
A bioguided fractionation procedure of an aqueous extract of the leaves of Apocynum venetum
using the EPM test led to the identification of kaempferol (72) as one of the active principles [69].
Examination of the isolated substance led to an increase in the time spent in the open arms at doses
from 0.02 to 1.0 mg/kg after oral administration. Vissiennon et al. also found the compound to be
anxiolytic in the EPM test at a dose of 1 mg/kg p.o., but not after intraperitoneal application of the
same dose [70]. The same effect was observed for quercetin (73), which increased open arm entries
and the time spent in the open arms already at a dose of 0.5 mg/kg p.o. The authors thereupon
investigated the metabolites of these two compounds and found para-hydroxy-phenylacetic acid to
be active in the same way after i.p. administration. After gut sterilization of the mice used in the
study with enrofloxaxin and oral administration of kaempferol and quercetin no anxiolytic-like effect
was observed. Thus, the authors concluded that both compounds act as prodrugs, which need to be
activated by the intestinal flora.
Rutin (75), a flavonol diglycoside, was investigated for its effect on PTZ-induced seizures [71].
I.c.v. injection of 5 µL of 50 nM solution prolonged the latency of general tonic-clonic seizures,
whereas injection of a 150 nM solution also increased the latency of minimal clonic seizures.
The C-glycoside vitexin (76) was also effective on both parameters at concentrations of 100 and
200 nM [72]. Pre-treatment with flumazenil (5 nM) abolished the anticonvulsant effects.
Spinosin (77) was isolated from Ziziphus spinosa and tested for its anxiolytic-like properties [73].
In the EPM test, spinosin increased the open arm entries and the time spent in the open arms at doses
of 2.5 and 5 mg/kg. In the light/dark test, an increase in transitions and time spent in the light area
was measured at a dose of 5 mg/kg. At the same dose, an increased number of entries into the centre
was observed in the open field test. All effects were antagonized by flumazenil and WAY-100635,
indicating that the effects are modulated by both, GABA(A) as well as 5-HT1A receptors.
Amentoflavone (78), a biflavone, was isolated from Hypericum perforatum and measured against
[3H]flumazenil in a radioligand binding assay, giving an IC50 value of 14.9 nM [74]. In the same study,
the compound was found to pass the blood-brain barrier in vitro by passive diffusion.
Amentoflavone, together with agathisflavone (79), was also isolated from Rhus pyroides, which is
now classified as Searsia pyroides [58]. Both compounds were studied in a radioligand binding assay
with [3H]flumazenil and showed Ki values of 37 and 28 nM, respectively.
Phytochemical investigations on Rhus parviflora, a taxon which is still unresolved, led to the
isolation of agathisflavone, rhusflavone (80) and mesuaferrone B (81), which were tested against
[35S]TBPS [75]. The compounds showed Ki values of 91, 45 and 280 nM, and IC50 values of 149, 73 and
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455 nM, respectively. Rhusflavone additionally decreased sleep latency in the pentobarbital-induced
sleeping test at doses of 12.5, 25 and 50 mg/kg and prolonged sleep duration at doses of 25 and
50 mg/kg. Pre-administration of flumazenil (8 mg/kg) reduced sleep duration and increased sleep
latency at a dose of 50 mg/kg rhusflavone.
The structure-activity findings observed for the flavones isolated from Scutellaria baicalensis
are confirmed when looking at the data of the other reported flavones. The effect of the 5,7-
dihydroxy-susbtitution also becomes obvious when comparing hispidulin (66) to cirsimaritin (67)
or dinatin (70) to skrofulein (71), where methylation of the hydroxy-group in position 7 leads to
higher Ki or IC50 values. The IC50 values of apigenin (63) and hispidulin (66) in the [3H]flumazenil
binding assay, on the other hand, demonstrate increased affinity through methoxylation in position 6.
The third finding, in which the hydroxylation in position 2’ increases affinity, cannot be confirmed
directly, but considering the nanomolar IC50 value of amentoflavone (78) in the [3H]flunitrazepam
binding assay, it seems that the 7-hydroxy-group of the second monomer has a similar impact on
the receptor affinity. Regarding the affinity of flavones to the TBPS/picrotoxin binding site, all four
tested flavones (65,79–81) showed sub-micromolar IC50 and Ki values (against [35S]TBPS). In terms
of receptor modulation, most flavones are reported to exhibit negative allosteric modulation, apart
from wogonin (46) and hispidulin (66), which show weak potentiation of GABA-induced ion currents.
In vivo studies revealed anxiolytic properties for apigenin (63), kaempferol (72) and quercetin (73).
Thereby, the latter two compounds were found to be prodrugs, with para-hydroxyphenylacetic acid as
the active metabolite.
3.3.2. Flavanes
In contrast to the high number of flavones, the group of GABA(A) receptor modulating flavanes
only consists of 14 compounds (Figure 5).
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(+)- and (−)-catechin (82 and 83) have been tested for their effect on [3H]γ-hydroxybutyric acid
(GHB) binding and on the binding of [3H]NCS-382, a GHB antagonist in order to find new lead
compounds for the GHB high-affinity site of the GABA(A) receptor [76]. (+)-catechin enhanced
[3H]NCS-382 binding to 163% and decreased [3H]GHB-binding to 54%, whereas (−)-catechin was
less active. (+)-catechin was subsequently investigated on GABA(A) receptors composed of α4β4δ
subunits expressed in Xenopus oocytes, where it exhibited a stimulation of 68% at a concentration of
100 µM.
(−)-epigallocatechin (84) at a concentration of 100 µM inhibited responses to 40 µM GABA up to
90.6% and that of 20 µM GABA up to 97% with IC50 values of 14.7 and 8.7 µM, respectively [55].
Furthermore, the compound reduced sleeping latency and prolonged sleep duration in the
pentobarbital-induced sleeping test at doses from 5 to 20 mg/kg p.o. [77].
(S)-naringenin (85) was isolated from an ethanolic leaf extract of Mentha aquatica and tested against
[3H]flumazenil, showing an IC50 value of 26 mM [78].
(2S)-hesperidin (86) at a dose of 4 mg/kg was found to decrease locomotor activity and reduce
the exploration of holes as well as the number of rearings in the holeboard test [63]. The compound at
the same dose increased the thiopental-induced sleeping time. The same levels of sleeping time were
achieved at a dose of 2 mg/kg in combination with 1 mg/kg of apigenin (63).
(2S)-5,7,8,4′-tetrahydroxyflavone (87) is one of the few flavanones from Scutellaria baicalensis
isolated by Wang et al. with an IC50 value of 21.4 µM against [3H]flunitrazepam [41].
Yang et al. isolated three 8-lavandulyl flavanones with GABAergic activity, (−)-kurarinone (88),
kushenol I (89) and sophoraflavanone G (90) from the Chinese herbal drug Kushen (Sophora flavescens)
and investigated the potentiation of GABA-induced chloride currents in Xenopus oocytes [79]. At a
concentration of 10 µM the compounds exhibited a potentiation of 719.7, 216.5 and 211.6%, with EC50
values of 4.0, 5.0 and 15.0 µM, respectively.
Glabrol (91), a prenylated flavanone from liquorice, was tested against [3H]flumazenil with an Ki
value of 1.63 µM [80].
Kim et al. isolated three Diels-Alder type adducts, sanggenon C (92), sanggenon D isomer (93) and
sanggenon G (94) from the root bark of Morus alba [81]. All three compounds enhanced GABA-induced
chloride currents by more than 700% (at 100 µM), with EC50 values from 13.4 to 16.7 µM.
As mentioned in the last subsection, Scutellaria baicalensis also yielded several flavanones, which
altogether showed much lower receptor affinities than their corresponding flavones. However, other
studies resulted in the isolation of prenylated flavanones, which did exhibit noteworthy effects.
Two 8-lavandulyl-flavanones (88 and 90), for example, caused a potentiation of GABA-induced
chloride currents of around 600%. The third one (89), an 8-lavandulyl-flavanonol, was significantly
less active. Three other prenylated flavanones (92–94) even exhibited stimulations of more than 700%.
Glabrol (91) was the only prenylated flavanone investigated for receptor affinity and showed a Ki of
1.63 against [3H]flumazenil, which was far lower than any tested unprenylated flavanone, indicating
that prenylation can lead to both, higher receptor affinity as well as pronounced potentiation of
chloride currents.
3.3.3. Isoflavonoids and Chalcones
Due to the limited number of reports, isoflavones (including one isoflavane) and chalcones will
be discussed in one subsection (Figure 6).
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Figure 6. Chemical structures of isoflavonoids and chalcones with reported GABA(A)-receptor
modulating activity.
2′,4′,7-trihydroxy-8-(3-methylbut-2-en-1-yl)isoflavone (95), which was isolated from Adenocarpus
cinncinatus, exhibited a potentiation of GABA-induced chloride currents of 552.73% at a concentration
of 500 µM, with an EC50 value of 2.8 µM [82].
Genistein (96) at a concentration of 100 µM inhibited responses to 40 µM GABA up to 51% with
an IC50 value 29.2 µM [55].
Glabridine (97), another compound from liquorice, showed remarkable effects on GABA(A)
receptors expressed in dorsal raphe neurons [83]. The compound enhanced GABA-induced chloride
currents by 135% at a concentration of only 30 nM, with a maximal potentiation of 581% at a
concentration of 3 µM.
Cho et al. investigated isoliquiritigenin (98) with a patch-clamp technique on dorsal raphe neurons,
where the compound enhanced GABA-induced currents by 151% at a concentration of 10 µM [84].
Further characterization of the compound resulted in a Ki value of 0.453 µM in a radioligand assay
with [3H]flunitrazepam as well as a decrease of sleep latency and an increase in sleep duration at doses
of 25 and 50 mg/kg p.o.
Kuraridine (99), a lavandulyl chalcone from Sophora flavescens potentiated GABA-induced chloride
currents by 719.7% at a concentration of 10 µM with a maximum stimulation of 891.5% [79]. The EC50
value was calculated with 4.0 µM.
Xanthohumol (100), a chalcone found in hops (Humulus lupulus), enhanced Mu-Alexa binding
from 5.2 nM to 6.1 nM at a concentration of 75 nM [85].
The results for isoflavonoids and chalcones are in accordance with the findings of the last two
subsections: the isoflavone genistein (96) inhibits chloride currents in the same manner as its flavone
counterpart apigenin (63) and the chalcone isoliquiritigenin (98) blocks [3H]flunitrazepam binding
as efficiently as many of the before mentioned flavones. In addition, also here, the prenylated forms
exhibit pronounced potentiation from over 500% (95,97) to almost 900% (99).
3.3.4. Phenylpropanes, Kavalactones and Lignans
This subsection contains simple and condensed phenylpropanes as well as one kavalactone
(Figure 7).
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Methyleugenol (101) was investigated on GABA(A) receptors expressed in HEK-293T cells and
identified as direct agonist with a stimulation of 290% [86].
β-asarone (102), isolated from Acorus calamus, showed a remarkable maximal potentiation of
GABA-induced chloride currents in a Xenopus oocyte assay of 1200% at a concentration of 500 µM [87].
However, the calculated EC50 value of 171.5 µM was rather high.
Another compound with a pronounced stimulation of GABA-induced chloride currents is
honokiol (103), a dimeric phenylpropane from Magnolia officinalis [88]. Honokiol exhibited a maximal
stimulation (1315% at 300 µM) comparable to that of β-asarone, but showed a much lower EC50 value
(36.2 µM). The effect was even higher at GABA(A) receptors composed of α3β2 subunits, reaching a
maximal stimulation of more than 2000%. In an earlier study, honokiol was already found to increase
the time spent in the open arms in an EPM test at a dose of 20 mg/kg p.o. and that the effect was
blocked by flumazenil (0.3 mg/kg s.c.) and bicuculline (0.1 mg/kg s.c.) [89]. Another study reported
that the compound increased the sleeping time in the pentobarbital-induced sleeping test at doses of
0.1 and 0.2 mg/kg p.o., but had no effect on the sleep latency [90]. Alexeev et al. tested honokiol and
magnolol (104) on different populations of neuronal and recombinant GABA(A) receptors, finding that
both compounds enhanced phasic and tonic GABAergic neurotransmission and that the compounds
were active on all subtypes [91]. The authors conclude that the modulation of synaptic as well as
extra-synaptic populations of GABA(A) receptors could lead to significant side effects and risk of
drug interactions.
Ma et al. isolated obovatol (105) from Magnolia obovata and reported the compound enhance the
pentobarbital-induced sleeping time at doses of 0.05, 0.1 and 0.2 mg/kg p.o. [92]. Furthermore, obovatol
significantly increased the chloride influx into the cultured cerebral granule cells and increased the
expression of α-, β- and γ-subunits.
Scheepens et al. investigated cinnamic acid (106), p-coumaric acid (107) and caffeic acid (108) on
GABA(A) receptors expressed in HEK-293T cells [93]. All three compounds activated the receptor
with EC50 values of 10.1, 6.9 and 10.5 µM, respectively. Further studies on p-coumaric acid revealed
that the compound also exhibited anxiolytic effects in the EPM test at 30 and 90 mg/kg and that the
effect was blocked by picrotoxin.
Electrophysiological experiments on sinapic acid (109) showed a stimulation of GABA-induced
chloride currents of 158% at a concentration of 10 µM and an EC50 value of 42.58 nM [94]. At a dose of
4 mg/kg p.o. The compound was also found to increase the number of head dips in the holeboard
test and the time spent in the open arms in the EPM test. Both bicuculline (5 mg/kg) and flumazenil
(10 mg/kg) reversed the effect.
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Dihydrokavain (110) is the only kavalactone with reported GABA(A) receptor modulation,
enhancing chloride currents by 31.5% at a concentration of 300 µM and showing an EC50 value
of 93 µM [95].
Zaugg et al. isolated zuihonin A (111), arisantetralones A–D (112–115) and four acylic lignans
(116–119) with GABAergic activity from Kadsura longipedunculata [96]. In a Xenopus oocyte assay highest
stimulation of chloride currents was observed for arisantetralone B (885.8%) and dihydroguaiaretic
acid (793.4%), while the lowest EC50 values were found for saururenin (12.8 µM) and zuihonin A
(21.8 µM).
Gomisin N (120) was isolated from Schisandra chinensis and investigated on the potentiation of
hypnotic effects in the pentobarbital-induced sleeping test [97]. The compound reduced sleep latency
and prolonged sleep duration at concentrations of 15, 30 and 45 mg/kg. Co-application of flumazenil
(8 mg/kg) reduced sleep duration but did not increase sleep latency.
In this subsection, only the lignans allow a structure-activity discussion, as nine compounds were
investigated in the same test system (111–119). Of these nine compounds, those two exhibited the
highest potentiation, which were substituted with one hydroxy- and one methoxy-group on both
aromatic rings (113,118). If only one ring had this substitution pattern, a methylenedioxo-group was
superior to two hydroxy-groups in the second ring. The substitution pattern with one hydroxy-group
next to a methoxy-group is reminiscent of the increased receptor affinity of flavones, where highest
affinity was observed for a 5,7-dihydroxy-6,8-dimethoxy-substitution pattern.
3.3.5. Coumarins
Eleven coumarins were reported to possess GABAergic activity, of which seven belong to the
subclass of linear furanocoumarins (Figure 8).
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and oxypeucedanin showed the lowest EC50 values (14 and 25 µM) and were therefore investigated 
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100 µM exhibited a potentiation of 550%, while osthol was significantly less active (124%). 
Osthol was also isolated from Angelica pubescens together with imperatorin, cnidilin (126), 
columbianedin (128) and columbianetin acetate (129), but only osthol showed a noteworthy 
potentiation of GABA-induced chloride currents [100]. In a study on the protection against MES-
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at a dose of 5 mg/kg p.o. in the holeboard test [103]. At the same dose, both compounds caused an 
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concentration of 500 µM) and an EC50 value of 140.2 µM [106]. 
Regarding the structure-activity relationship of coumarins, Singhuber et al. found the prenyl 
residue essential for positive GABA(A) receptor modulation, with oxyprenylated oxypeucedanin 
(124) exhibiting the highest potentiation. Additional findings were that both, bulkier moieties as well 
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First reports were by Bergendorff et al., wh isolated imperatorin (121), phellopterin
(122) and byakangelicol (123) from the roots of Angelic dahurica and sted their affinity to the
benzodiazepine binding site using [3 ] i [ ]. IC50 values of the three compounds were 8.0,
0.36 and 12 µM, respectively.
Imperatorin and phellopterin were also investigated on GABA(A) receptors expressed in Xenopus
oocytes along with oxypeucedanin (124), isoimperatorin (125) and osthol (127) [99]. Osthol and
oxypeucedanin showed the lowest EC50 values (14 and 25 µM) and were therefore investigated for
their stimulation of GABA-induced chloride currents. Here, oxypeucedanin at a concentration of
100 µM exhibited a potentiation of 550%, while osthol was significantly less active (124%).
Osthol was also isolated from Angelica pubescens together with imperatorin, cnidilin (126),
columbianedin (128) and columbianetin acetate (129), but only osthol showed a noteworthy
potentiation of GABA-induced chloride currents [100]. In a study on the protection against
MES-induced seizures osthol exhibited protective effects at doses from 259 to 631 mg/kg [101].
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Similar results were obtained for imperatorin showing protection at a dose of 300 mg/kg [102].
Imperatorin as well as isoimperatorin showed a decrease in head dip latency and an increased number
of rearings at a dose of 5 mg/kg p.o. In the holeboard test [103]. At the same dose, both compounds
caused an increase in the number of open arm entries and time spent in the open arms in the EPM test,
as well as a decrease in closed arm entries and time spent in the closed arms. In the light/dark test
both compounds increased the time spent in the light area and decreased the time spent in the dark
area at a dose of 5 mg/kg p.o., with isoimperatorin additionally increasing the number of crossings.
Xanthotoxin (130), a furanocoumarin isolated from Pastinaca sativa, was tested for its protection
against MES-induced convulsions [102,104,105]. Luszczki et al. found the compound to be protective
at a dose of 300 mg/kg [102]. Skalicka-Wozniak et al. calculated median protective doses against
hind limb tonic extension from 219 to 252 mg/kg [104], and Zagaja et al. found the compound to
be protective from hind limb tonic extension at a dose of 150 mg/kg [105]. Another finding of the
latter study was that xanthotoxin enhanced the anticonvulsive effect of carbamazepin and valproate at
100 mg/kg.
The only GABA(A) receptor-modulating isocoumarin (131) was isolated from Haloxylon scoparium,
but the compound showed only moderate stimulation of chloride currents (144.6% at a concentration
of 500 µM) and an EC50 value of 140.2 µM [106].
Regarding the structure-activity relationship of coumarins, Singhuber et al. found the prenyl
residue essential for positive GABA(A) receptor modulation, with oxyprenylated oxypeucedanin (124)
exhibiting the highest potentiation. Additional findings were that both, bulkier moieties as well as the
lack of the C5-side chain lead to a loss of activity and that angular furanocoumarins are less active
than linear furanocoumarins. The authors furthermore stated that the reported coumarins are not
acting via the benzodiazepine binding site. Data of additional studies on coumarins confirms the
reduced acitivity of angular furanocoumarins. In terms of receptor affinity instead, prenyl moieties
show higher affinities than epoxyprenyl residues. As only one isocoumarin was reported to possess
(moderate) GABAergic acitivity, no general conclusions can be drawn for this compound (sub)class.
3.3.6. Diarylheptanoids, Stilbenes and Phenanthrenes
This subsection contains the diarylheptanoid curcumin, two phenanthrenes, stilbenes and
dihydrostilbenes (Figure 9).
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Curcumin (132) was isolated from the oil of Curcumae rhizoma and tested on GABA(A) 
receptors expressed in HEK-293T cells, where the compound exhibited a maximal stimulation of 
120% at a concentration of 50 µM [107]. 
Resveratrol (133), a prominent stilbene known from red wine, was studied by Hamid et al., 
together with trans-ε-viniferin (134) [108]. While resveratrol was found to moderately stimulate 
GABA-induced chloride currents (126% at a concentration of 100 µM), with an EC50 value of 58.24 
µM, trans-ε-viniferin was identified as GABA(A) receptor inhibitor, with an IC50 value of 5.79 µM. 
Rueda et al. isolated the stilbene pholitodol D (135) and its dihydro-derivative batatasin III (136) 
from Pholidota chinensis [109]. At a concentration of 300 µM both compounds showed a pronounced 
stimulation of GABA-induced chloride currents in the Xenopus laevis oocyte assay, with a maximal 
stimulation of 786.8% found for pholitodol D and 1512.9% for batatasin III, with EC50 values of 175.5 
and 52.5 µM, respectively. The authors conclude that the conformational flexibility is the reason for 
the increased receptor stimulation of batatasin III, a theory which was confirmed by measuring 13 
commercially available stilbenes and their corresponding dihydro-derivatives. 
Another series of stilbenoids (137–139) with noteworthy activities was isolated from the roots 
and tubers from Adenocarpus cincinnatus [82]. At a concentration of 500 µM the compounds 
potentiated GABA-induced ion currents in a range from 491 to 771%, with EC50 values of 40.7 (137), 
8.6 (138) and 18.8 µM (139). 
Effusol (140) and dehydroeffusol (141) were isolated from Juncus effusus and found to modulate 
GABA(A) receptors with EC50 values of 31 and 27 µM [110]. At a concentration of 300 µM, the 
compounds exhibited maximal stimulations of 188 and 239%, respectively. 
The increased receptor modulation of dihydrostilbenes in comparison to stilbenes has already 
been proven by studies with semi-synthetic dihydro-derivatives and is also evident in the two-fold 
higher potentiation and the three times lower EC50 of batatasin III (136) compared to pholitodol (135). 
Prenylated dihydrostilbenes (137–139) show a maximal potentiation in the range of pholitodol, but 
lower EC50 values than both before mentioned compounds. Here, the compound bearing an open 
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Curcumin (132) was isolated from the oil of Curcumae rhizoma and tested on GABA(A) receptors
expressed in HEK-293T cells, where the compound exhibited a maximal stimulation of 120% at a
concentration of 50 µM [107].
Resveratrol (133), a prominent stilbene known from red wine, was studied by Hamid et al.,
together with trans-ε-viniferin (134) [108]. While resveratrol was found to moderately stimulate
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GABA-induced chloride currents (126% at a concentration of 100 µM), with an EC50 value of 58.24 µM,
trans-ε-viniferin was identified as GABA(A) receptor inhibitor, with an IC50 value of 5.79 µM.
Rueda et al. isolated the stilbene pholitodol D (135) and its dihydro-derivative batatasin III (136)
from Pholidota chinensis [109]. At a concentration of 300 µM both compounds showed a pronounced
stimulation of GABA-induced chloride currents in the Xenopus laevis oocyte assay, with a maximal
stimulation of 786.8% found for pholitodol D and 1512.9% for batatasin III, with EC50 values of 175.5
and 52.5 µM, respectively. The authors conclude that the conformational flexibility is the reason for
the increased receptor stimulation of batatasin III, a theory which was confirmed by measuring 13
commercially available stilbenes and their corresponding dihydro-derivatives.
Another series of stilbenoids (137–139) with noteworthy activities was isolated from the roots and
tubers from Adenocarpus cincinnatus [82]. At a concentration of 500 µM the compounds potentiated
GABA-induced ion currents in a range from 491 to 771%, with EC50 values of 40.7 (137), 8.6 (138) and
18.8 µM (139).
Effusol (140) and dehydroeffusol (141) were isolated from Juncus effusus and found to modulate
GABA(A) receptors with EC50 values of 31 and 27 µM [110]. At a concentration of 300 µM,
the compounds exhibited maximal stimulations of 188 and 239%, respectively.
The increased receptor modulation of dihydrostilbenes in comparison to stilbenes has already
been proven by studies with semi-synthetic dihydro-derivatives and is also evident in the two-fold
higher potentiation and the three times lower EC50 of batatasin III (136) compared to pholitodol
(135). Prenylated dihydrostilbenes (137–139) show a maximal potentiation in the range of pholitodol,
but lower EC50 values than both before mentioned compounds. Here, the compound bearing an open
oxyprenylated side chain (138) shows the lowest value, followed by prenylated compound 139 and
isoneorautenol (137), which has a cyclized prenyl moiety.
3.3.7. Simple Phenols and Polyphenols
In this subsection, simple phenols and their condensed forms will be discussed (Figure 10).
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4-Hydroxybenzaldehyde (142) was identified as one of two active principles in an aqueous 
extract of Gastrodia elata, by increasing the number of open arm entries at doses 50 and 100 mg/kg and 
time spent in the open arm at a dose of 100 mg/kg in the EPM test [111]. In contrast to the other active 
constituent, 4-hydroxybenzylalcohol (which was antagonized by WAY-100635), the effects of 142 
were blocked by flumazenil. 
p-pentylphenylbenzoate (143) was isolated from the Nigerian medicinal plant Mondia whitei and 
was found to decrease exploratory activity in the holeboard test and locomotor activity, rearing and 
grooming in the open field test at doses of 100, 200 and 300 mg/kg [112]. The compound also increased 
the time spent in the open arms of an EPM test at a dose of 300 mg/kg. However, GABA(A) receptor 
binding was only suggested by a computational model and not confirmed by co-application of a 
GABA(A) receptor antagonist. 
Embellin (144), a benzoquinone isolated from Embelia ribes, was reported to have anticonvulsant 
activities [113]. In the MES-induced seizure model, embelin caused a reduction of hindlimb tonic 
extensions at doses of 2.5 and 5 mg/kg. At a dose of 10 mg/kg no hindlimb tonic extensions were 
observed. In the PTZ-induced seizures model embelin increased the onset of clonic and tonic action 
at doses of 2.5, 5 and 10 mg/kg and exhibited 50% (5 mg/kg) and 83% (10 mg/kg) protection against 
mortality. Embellin also reduced locomotor activity at all three doses. 
Cho et al. isolated four phlorotannis (145–148) from the edible brown seaweed Ecklonia cava and 
measured their GABA(A) receptor affinity against [35S]TBPS [114]. The obtained Ki values were 4.419 
(triphlorethol-A), 1.070 (eckol), 3.072 (dieckol) and 1.491 µM (eckstolonol), and IC50 values were 
calculated with 7.180, 1.739, 4.991 and 2.422 µM, respectively. 
The reported polyphenolic compounds show comparable receptor affinities. Because of this and 
the fact that the same structural features appear repeatedly, a discussion on the structure-acitivity 
relationship of this compound class seems pointless. 
3.4. Terpenes 
3.4.1. Monoterpenes 
A total of 28 monoterpenes with GABA(A) receptor modulating activity have been reported, 
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Figure 10. Chemical structures of simple phenols and polyphenols with reported GABA(A)-receptor
modulating activity.
4-Hydroxybenzaldehyde (142) was identified as one of two active principles in an aqueous extract
of Gas rodia ela a, by incre sing the number of ope arm entries at doses 50 nd 100 mg/kg and time
spent in the open arm at a dose of 100 mg/kg in the EPM test [111]. In contrast to the ther active
constituent, 4-hydroxybenzylalcohol (which was antagonized by WAY-100635), the effects of 142 were
blocked by flumazenil.
p-pentylphenylbenzoate (143) was isolated from the Nigerian medicinal plant Mondia whitei and
was found to decrease exploratory activity in the holeboard test and locomotor activity, rearing and
grooming in the open field test at doses of 100, 200 and 300 mg/kg [112]. The compound also increased
the time spent in the open arm of an EPM test at a dose of 300 mg/kg. However, GABA(A) receptor
binding was only suggest d by a computational model and not confirmed by co-application of a
GABA(A) receptor antagonist.
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Embellin (144), a benzoquinone isolated from Embelia ribes, was reported to have anticonvulsant
activities [113]. In the MES-induced seizure model, embelin caused a reduction of hindlimb tonic
extensions at doses of 2.5 and 5 mg/kg. At a dose of 10 mg/kg no hindlimb tonic extensions were
observed. In the PTZ-induced seizures model embelin increased the onset of clonic and tonic action at
doses of 2.5, 5 and 10 mg/kg and exhibited 50% (5 mg/kg) and 83% (10 mg/kg) protection against
mortality. Embellin also reduced locomotor activity at all three doses.
Cho et al. isolated four phlorotannis (145–148) from the edible brown seaweed Ecklonia cava
and measured their GABA(A) receptor affinity against [35S]TBPS [114]. The obtained Ki values were
4.419 (triphlorethol-A), 1.070 (eckol), 3.072 (dieckol) and 1.491 µM (eckstolonol), and IC50 values were
calculated with 7.180, 1.739, 4.991 and 2.422 µM, respectively.
The reported polyphenolic compounds show comparable receptor affinities. Because of this and
the fact that the same structural features appear repeatedly, a discussion on the structure-acitivity
relationship of this compound class seems pointless.
3.4. Terpenes
3.4.1. Monoterpenes
A total of 28 monoterpenes with GABA(A) receptor modulating activity have been reported,
including one cinnamoyl derivative (Figure 11).Molecules 2018, 23, x FOR PEER REVIEW  17 of 42 
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sleeping latency in the phenobarbital-induced sleeping test at doses from 5 to 20 mg/kg p.o. [116]. At 
doses of 50, 100 and 200 mg/kg p.o. (−)-borneol increased latency and protection against PTZ-induced 
convulsions, an effect that was antagonized by flumazenil. 
Höld et al. tested α-thujone (154) and β-thujone (155) against [³H]EBOB in a radioligand binding 
assay, where the compounds showed IC50 values of 13 and 37 µM [117]. Additional 
electrophysiological investigations identified α-thujone as non-competitive antagonist with an IC50 
value of 21 µM. The allosteric reduction of GABA-induced chloride currents was confirmed by 
Czyzewska et Mozrzymas, who measured a decrease in stimulation of 60% at a concentration of 300 
µM [118]. In a study on GABAergic miniature inhibitory currents, α-thujone was found to reduce 
their frequency and amplitude and moderately affected their kinetics. Because the compound also 
reduced the amplitude of current responses to exogenous GABA and affected their onset, 
desensitization and deactivation, the authors assume α-thujone to have receptor gating effects [119]. 
A mixture of both enantiomers was tested for their effect on GABA-induced enhancement of 
[³H]flunitrazepam binding [120]. Thujone reduced the maximal enhancement of GABA from 182 to 
103%, confirming the negative allosteric mechanism of the compound. In the same study, (+)-carvone 
(156) and (−)-carvone (157) were investigated. While (−)-carvone decreased enhancement of GABA to 
only 116%, (+)-carvone was even more effective than thujone, with a decrease to 74%. 
α,β-epoxy-carvone (158) was investigated for its anticonvulsant properties using MES-, PTZ- 
and picrotoxin-induced seizure models [121]. α,β-epoxy-carvone was protective against MES- and 
picrotoxin-induced seizures at doses of 200, 300 and 400 mg/kg and increased the latency of 
picrotoxin-induced seizures at 300 and 400 mg/kg. At the latter doses, the compound was also 
protective against PTZ-induced seizures. The observed anticonvulsant effects were not affected after 
pretreatment with flumazenil. 
Safranal (159) also showed anticonvulsant effects in the PTZ-induced seizures model, where it 
decreased the incidence of minimal clonic seizures and generalized tonic clonic seizures at a dose of 
145.5 mg/kg and increased latency of both types [122]. Flumazenil abolished the protective effects of 
safranal, indicating involvement of GABA(A) receptors. However, after intracerebroventricular 
injection of safranal, no anticonvulsant effects were observed. 
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Granger et al. investigated (+)-borneol (149), (−)-borneol (150), (−)-bornyl acetate (151),
isoborneol (152) and camphor (153) on GABA(A) receptors expressed in Xenopus laevis oocytes [115].
All compounds caused pronounced maximal potentiation of GABA-induced chloride currents, with the
highest stimulation observed for (+)-borneol (1251%) and (−)-borneol (1106%). However, EC50 values
were in a high micromolar range with the lowest value observed for bornyl acetate (111.2 µM).
(−)-borneol was also studied in vivo, it o ed a prolongation of sleeping time an reduced
sleeping latency in the phenobar i uced sl eping tes at doses from 5 to 20 mg/kg p.o. [116].
At of 50, 100 and 200 mg/kg p.o. (−)-borneol incre sed la ncy nd protection against
PTZ-induced convulsions, an effect that was antagonized by flumazenil.
Höld et al. tested α-thujone (154) and β-thujone (155) against [3H]EBOB in a radioligand
binding assay, where the compounds showed IC50 values of 13 and 37 µM [117]. Additional
electrophysiological investigations identified α-thujone as non-competitive antagonist with an IC50
value of 21 µM. The allosteric reduction of GABA-induced chloride currents was confirmed by
Czyzewska et Mozrzymas, who measured a decrease in stimulation of 60% at a concentration of
300 µM [118]. In a study on GABAergic miniature inhibitory currents, α-thujone was found to
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reduce their frequency and amplitude and moderately affected their kinetics. Because the compound
also reduced the amplitude of current responses to exogenous GABA and affected their onset,
desensitization and deactivation, the authors assume α-thujone to have receptor gating effects [119].
A mixture of both enantiomers was tested for their effect on GABA-induced enhancement of
[3H]flunitrazepam binding [120]. Thujone reduced the maximal enhancement of GABA from 182 to
103%, confirming the negative allosteric mechanism of the compound. In the same study, (+)-carvone
(156) and (−)-carvone (157) were investigated. While (−)-carvone decreased enhancement of GABA to
only 116%, (+)-carvone was even more effective than thujone, with a decrease to 74%.
α,β-epoxy-carvone (158) was investigated for its anticonvulsant properties using MES-, PTZ-
and picrotoxin-induced seizure models [121]. α,β-epoxy-carvone was protective against MES- and
picrotoxin-induced seizures at doses of 200, 300 and 400 mg/kg and increased the latency of
picrotoxin-induced seizures at 300 and 400 mg/kg. At the latter doses, the compound was also
protective against PTZ-induced seizures. The observed anticonvulsant effects were not affected after
pretreatment with flumazenil.
Safranal (159) also showed anticonvulsant effects in the PTZ-induced seizures model, where it
decreased the incidence of minimal clonic seizures and generalized tonic clonic seizures at a dose of
145.5 mg/kg and increased latency of both types [122]. Flumazenil abolished the protective effects
of safranal, indicating involvement of GABA(A) receptors. However, after intracerebroventricular
injection of safranal, no anticonvulsant effects were observed.
Thymol (160), an aromatic monoterpene known from several Thymus species, was investigated on
α1β3γ2 receptors expressed in Xenopus oocytes, where it potentiated GABA-induced chloride currents
by 416% at a concentration of 100 µM [123]. It also evoked small currents in the absence of GABA.
Garcia et al. investigated the effects of thymol on [3H]flunitrazepam binding [124]. Thymol thereby
caused a maximum response of [3H]flunitrazepam binding, with an EC50 value of 130.9 µM.
Kessler et al. tested twelve monoterpenes (161–171) contained in an extract of Sideritis sp. on
GABA(A) receptors expressed in both, Xenopus laevis oocytes and HEK-293T cells [33]. Of the tested
compounds (+)-cis-verbenol (166) and (−)-myrtenol (171) showed pronounced effects, potentiating
GABA-induced chloride currents by 809% and 737%, respectively.
Isopulegol (163) was investigated in vivo for its anxiolytic potential and was found to increase
the number of head dips in the holeboard test at doses of 25 and 50 mg/kg [125]. At the same doses
isopulegol increased the number of open arm entries and time spent in the open arms and decreased the
number of closed arm entries and time spent in closed arms in the EPM test. However, at theses doses
an increased immobility time in the forced swim test and the tail suspension test were also observed.
Viana et al. studied (−)-myrtenol (171) for its gastroprotective effect against ethanol-induced
acute gastric lesions [126]. The compound caused a decrease of gastric lesions at doses of 25, 50
and 100 mg/kg p.o. Pretreatment with flumazenil (20 mg/kg) reduced the gastroprotective effect of
50 mg/kg (−)-myrtenol.
In a study on the anxiolytic-like action of (+)-limonene expoxide (172), the compound showed an
increase in open arm entries and time spent in the open arms at doses of 25, 50 and 75 mg/kg in the
EPM test [127]. At the same doses a reduced number of crossing, rearing and grooming was observed
in the open field test, furthermore indicating sedative effects of the compound. At a dose of 75 mg/kg
increased number of falls and reduced time of permanence on the bar were measured, an effect that
was reversed by flumazenil. The anxiolytic-like effect of (+)-limonene expoxide was confirmed by a
follow-up study, where the compound showed a reduction in the number of buried marbles at 25, 50
and 75 mg/kg in the buried marbles test [128].
Also, carvacryl acetate (173) was investigated for its anxiolytic-like and sedative effects in several
experiments [129]. In the EPM test the compound increased the number of open arm entries at a dose
of 100 mg/kg and the time spent in the open arm at doses from 25 to 100 mg/kg. In the light/dark test
carvacryl acetate increased the number and time spent in the light area at doses from 25 to 100 mg/kg.
Both effects were blocked by flumazenil (25 mg/kg) but not by WAY-100635 (10 mg/kg). In the buried
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marbles test, a reduced number of buried marbles was observed at doses from 25 to 100 mg/kg, but no
coordination impairment in the rotarod test and no decrease in locomotor activity in the open field test
was measured at the same doses.
(+)-citronellol (174) was studied for its anticonvulsant effects using the MES-, PTZ- and
picrotoxin-induced seizure models [130]. (+)-citronellol induced the latency of PTZ-induced seizures
at doses of 100, 200 and 400 mg/kg and reduced the number of convulsions at a dose of 400 mg/kg.
At this dose the compound was also protective against tonic extensions in the MES-induced seizures
model. In the picrotoxin-induced seizures test, (+)-citronellol showed an increased latency at doses of
200 and 400 mg/kg.
Electrophysiological studies on (+)-menthol (175), using the Xenopus laevis oocyte assay, revealed
a potentiation of GABA-induced chloride currents of 496% at a concentration of 100 µM [131] and
96.2% at a concentration of 50 µM, respectively [132]. The latter study determined an EC50 value of
23.5 µM and found the binding site of (+)-menthol to be distinct from benzodiazepines, steroids and
barbiturates, but similar to that of propofol.
The last monoterpene to be discussed is (+)-6-cinnamoyl-6,7-dihydro-7-myrceneol (176), which
was isolated from Kadsura longipedunculata and showed a maximum stimulation of GABA-induced
chloride currents of 834.6%, with an EC50 value of 70.6 µM [96].
Several monoterpenes have been investigated for their GABA receptor modulating activity and
thereof the highest potentiation of chloride currents was observed for bicyclic alocohols, like (+)- and
(−)-borneol (149,150), with maximal stimulations of more than 1100%. However, isoborneol (152),
(+)-cis-verbenol (166) and (−)-myrtenol (171) also exhibited pronounced potentiation. Oxidation of
the hydroxy-group or the presence of an exocyclic methylene group decreased the activity, as well as
ring opening. The only monocyclic monoterpenes with noteworthy positive receptor modulation are
thymol and carveol (160,162), eliciting a potentiation of over 400%. Interestingly, when oxidizing the
latter compound into carvone (156,157), the positive allosteric modulation is inverted, and chloride
currents are allosterically inhibited instead. An effect also observed both, α- and β-thujone (154,155).
3.4.2. Sesquiterpenes
A total of 28 sesquiterpenes with GABA(A) receptor modulating activity have been reported,
including one cinnamoyl derivative (Figure 12).
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Curdione (179) and curcumol (180) were isolated from the oil of Curcumae rhizoma and 
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compounds potentiated GABA-induced chloride currents with 133 and 175.7%, respectively. 
Curcumol was further investigated, showing an EC50 value of 34.4 µM and a maximal stimulation of 
251% (at a concentration of 300 µM). The compound also reduced locomotor activity in the open field 
test at a dose of 100 mg/kg. In a recent study by Liu et al., curcumol was reported to allosterically 
modulate the receptor at a binding site distinct from benzodiazepines [133]. 
Isocurcumenol (181), isolated from Cyperus rotundus, was analysed for its affinity to GABA(A) 
receptors using [³H]flumazenil and [³H]flunitrazepam, where it inhibited binding of the two ligands 
by 58.3 and 105.0%, respectively (at a concentration of 100 µM) [134]. 
Valerenic acid (182), isolated from Valeriana officinalis, caused a potentiation of GABA-induced 
chloride currents of 400% (at a concentration of 100 µM) with an EC50 value of 13.6 µM [135], thus 
confirming earlier reports of the possible GABAergic mechanism of valerian extracts [136]. In an EPM 
test, valerenic acid prolonged the time spent in the open arms at a dose of 3 mg/kg [137]. 
(+)-γ-cuparenol (183) and (+)-dihydrocuparenic acid (184), isolated from Kadsura 
longipedunculata, exhibited a maximal stimulation of GABA-induced chloride current of around 400%, 
with EC50 values of 57.3 and 118.4 µM, respectively [96]. 
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α-caryophyllene (177) and β-caryophyllene (178) were part of the study on monoterpenoids
from Sideritis sp. by Kessler et al., where they showed only moderate potentiation of GABA-induced
chloride currents (117 and 115%, respectively) [33].
Curdione (179) and curcumol (180) were isolated from the oil of Curcumae rhizoma and measured
on GABA(A) receptors expressed in HEK-293T cells [107]. At a concentration of 50 µM the compounds
potentiated GABA-induced chloride currents with 133 and 175.7%, respectively. Curcumol was further
investigated, showing an EC50 value of 34.4 µM and a maximal stimulation of 251% (at a concentration
of 300 µM). The compound also reduced locomotor activity in the open field test at a dose of 100 mg/kg.
In a recent study by Liu et al., curcumol was reported to allosterically modulate the receptor at a
binding site distinct from benzodiazepines [133].
Isocurcumenol (181), isolated from Cyperus rotundus, was analysed for its affinity to GABA(A)
receptors using [3H]flumazenil and [3H]flunitrazepam, where it inhibited binding of the two ligands
by 58.3 and 105.0%, respectively (at a concentration of 100 µM) [134].
Valerenic acid (182), isolated from Valeriana officinalis, caused a potentiation of GABA-induced
chloride currents of 400% (at a concentration of 100 µM) with an EC50 value of 13.6 µM [135],
thus confirming earlier reports of the possible GABAergic mechanism of valerian extracts [136].
In an EPM test, valerenic acid prolonged the time spent in the open arms at a dose of 3 mg/kg [137].
(+)-γ-cuparenol (183) and (+)-dihydrocuparenic acid (184), isolated from Kadsura longipedunculata,
exhibited a maximal stimulation of GABA-induced chloride current of around 400%, with EC50 values
of 57.3 and 118.4 µM, respectively [96].
(+)-dehydrofukinone (185), isolated from Nectandra grandiflora, was measured in the PTZ-induced
seizures model, where it delayed the onset of myoclonic jerks and generalized tonic clonic seizures at a
dose of 10 mg/kg p.o. and reduced the latency to generalized seizures at 10 and 100 mg/kg p.o. [138].
Viridoflorol (186) was isolated from Mentha aquatica and subjected to a radioligand binding assay
using [3H]flumazenil, but showed only weak receptor affinity with an IC50 value of 190 mM [78].
Aristol-1(10)-en-9-ol (187) from Nardostachys chinensis, now classified as Nardostachys jatamansi,
caused a prolongation of sleeping time in the pentobarbital-induced sleeping test after inhalation of a
dose of 300 µg/cage [139]. The effect was antagonized by flumazenil (3 mg/kg).
Five sesquiterpenes (188–192), isolated from the rhizomes of Acorus calamus, were measured in
the Xenopus oocyte assay, where they potentiated GABA-induced chloride currents from 164 to 886%
at concentrations of 300 to 1000 µM, with the lowest IC50 value calculated for (−)-acorenone (188,
34.0 µM [87].
Aristolactone (193), a compound known from Aristolochia manshuriensis, was isolated from an
adulterated commercial sample of Bupleurum chinense [140]. The compound was found to only
moderately potentiate GABA-induced chloride currents with a maximal stimulation of 70.7% at a
concentration of 1000 µM. The IC50 value of the compound was calculated as 56.02 µM.
Atractylenoids I (194), II (195) and III (196) were isolated from Atractylodes macrocephala and
tested on GABA(A) receptors expressed in Xenopus laevis oocytes [141]. At concentrations of 300 µM
the three compounds showed maximal potentiation of 96 to 166%, with EC50 values of 12, 70 and
99 µM, respectively.
Anisatin (197), a highly oxygenated sesquiterpene lactone from Illicium anisatum, was already
described as potent non-competitive antagonist of GABA(A) receptor in 1981, with similar effects to
those of picrotoxin [142,143]. Later studies in dorsal root ganglia found that anisatin at a concentration
of 1 µM reduced chloride currents evoked by 30 µM GABA by 41.7% [144]. The IC50 value was
calculated with 1.10 µM. In the same study, an IC50 value of 0.42 µM was determined for picrotoxinin,
the (more) active compound of picrotoxin. In a radioligand binding assay anisatin showed an IC50
value of 0.43 µM against [3H]EBOB, indicating that anisatin binds to the picrotoxin site of the receptor.
Another very potent sesquiterpene is xenovulene A, which has been isolated from the fungus
Acremonium strictum (now classified as Sarocladium strictum) [145]. The compound potentiated
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GABA-induced chloride currents by 180% at a concentration of 1 µM and showed an EC50 value
at a nanomolar level (0.05 µM).
Due to the structural differences of the reported sesquiterpenes only limited conclusions on their
structure-activity relationship can be drawn. One finding is that reduction of the acidic function of
compound 184 to an alcoholic function (183) does not seem to alter the acitivity, while the change of
the isopropenyl-function of compound 189 to a plane isopropanyl-moiety (190) leads to a significant
loss of activity.
3.4.3. Diterpenes
A total of 14 diterpenes with GABAergic activity will be discussed in this subsection (Figure 13).
Miltirone (199), a tanshinone from Salvia miltiorrhiza, was tested against [3H]flunitrazepam in a
radioligand binding assay, exhibiting an IC50 value of 0.3 µM [146]. In subsequent in vivo studies,
the compound increased the number of punished crossings in the four plates test at doses from
10 to 60 mg/kg p.o., but at the same doses showed no muscle relaxant effect and no impairment
in the horizontal wire test. Due to these findings the authors concluded miltirone to be acting
as a partial agonist on the benzodiazepine bindings site. These conclusions were confirmed by
Mostallino et al., who additionally reported that miltirone does not potentiate GABA-induced ion
currents in Xenopus laevis oocytes, but concentration-dependently inhibits the potentiation caused by
diazepam [147].Molecules 2018, 23, x FOR PEER REVIEW  21 of 42 
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Figure 13. Chemical structures of diterpenes with reported GABA(A)-receptor modulating activity. 
7-methoxyrosmanol (200) and galdosol (201), two compounds isolated from Salvia officinalis, 
were analysed in a radioligand assay using [³H]flumazenil [63]. IC50 values were calculated as 7.2 and 
0.8 µM, respectively. 
Dehydroabietic acid (202) was isolated from Boswellia thurifera, now classified as Boswellia serrata, 
and analysed in Xenopus laevis oocytes [148]. The compound potentiated GABA-induced chloride 
currents by 397.5% at 100 µM and showed an EC50 value of 8.7 µM. 
Isopimaric acid (203) and sandaropimaric acid (204) were isolated from Biota orientalis, which is 
meanwhile classified as Platycladus orientalis, and analysed in the Xenopus oocyte assay [149]. The 
compounds, at a concentration of 500 µM, exhibited a maximal potentiation of GABA-induced 
chloride currents of 425.2 and 855.7% and showed EC50 values of 141.6 and 33.2 µM, respectively. 
Maximal stimulation of chloride currents by both compounds was raised to over 1000%, when α1-
subunits were exchanged for α2- or α3-subunits.  
Two phyllocladane-type diterpenes (205,206) were isolated from Aloysia virgata and tested for 
their GABA(A) receptor affinity against [³H]flumazenil, showing Ki values of 111 and 56 µM, 
respectively [150]. Both compounds were subsequently analysed in vivo, with compound 205 
exhibiting increased locomotor activity at a dose of 1 mg/kg in the locomotor activity test and 
increased rearing at 0.3 and 1 mg/kg in the holeboard test. Compound 206 increased the number of 
head dips at 0.3 and 3 mg/kg, the number of rears at a dose of 1 mg/kg and the time spent head-
dipping at a dose of 3 mg/kg. Moreover, the compound at a dose of 1 mg/kg increased the number of 
open arm entries in the EPM test and the time spent in the light area as well as the number of 
transitions in the light/dark test. 
Zerumin A (207) and coronarin D (208), two labdan-type diterpenes, were isolated from Curcuma 
kwangsiensis [151]. The compounds, at a concentration of 300 µM, potentiated GABA-induced 
chloride currents in the Xenopus oocyte assay by 309.4 and 211.0%, respectively, with EC50 values of 
24.9 and 35.7 µM. 
Ginkgolides A (209), B (210) and C (211), diterpene trilactones from Ginkgo biloba, were found to 
be moderately potent antagonists at GABA(A) receptors expressed in Xenopus laevis oocytes, with Ki 
values of 14.5, 12.7 and 16.3 µM, respectively [152]. IC50 values of the three compounds were 11.9, 
10.1 and 12.0 µM, respectively. A study on ginkgolide B and bilobalide (212) using cortical neurons 
found the compounds to inhibit chloride currents by 63.2 and 46.8% at a concentration of 50 µM [153]. 
IC50 values of the compounds were 73 and 76 µM, respectively. A radioligand binding assay of 
bilobalide using [35S]TBPS determined a Kd value of 3.7 µM [154]. In the same study the impact on 
the flux of 36chloride was measured. Bilobalide, at a concentration of 1000 µM totally blocked chloride 
uptake into synaptoneurosomes but showed only low potency with an IC50 value of 39 µM. 
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7-methoxyrosmanol (200) and galdosol (201), two compounds isolated from Salvia officinalis, were
analysed in a radioligand assay using [3H]flumazenil [63]. IC50 values were calculated as 7.2 and
0.8 µM, respectively.
Dehydroabietic acid (202) was isolated from Boswellia thurifera, now classified as Boswellia serrata,
and analysed in Xenopus laevis oocytes [148]. The compound potentiated GABA-induced chloride
currents by 397.5% at 100 µM and showed an EC50 value of 8.7 µM.
Isopimaric acid (203) and sandaropimaric acid (204) were isolated from Biota orientalis,
which is meanwhile classified as Platycladus orientalis, and analysed in the Xenopus oocyte
assay [149]. The compounds, at a concentration of 500 µM, exhibited a maximal potentiation of
GABA-induced chloride currents of 425.2 and 855.7% and showed EC50 values of 141.6 and 33.2 µM,
respectively. Maximal stimulation of chloride currents by both compounds was raised to over 1000%,
when α1-subunits were exchanged for α2- or α3-subunits.
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Two phyllocladane-type diterpenes (205,206) were isolated from Aloysia virgata and tested for
their GABA(A) receptor affinity against [3H]flumazenil, showing Ki values of 111 and 56 µM,
respectively [150]. Both compounds were subsequently analysed in vivo, with compound 205
exhibiting increased locomotor activity at a dose of 1 mg/kg in the locomotor activity test and increased
rearing at 0.3 and 1 mg/kg in the holeboard test. Compound 206 increased the number of head dips
at 0.3 and 3 mg/kg, the number of rears at a dose of 1 mg/kg and the time spent head-dipping at a
dose of 3 mg/kg. Moreover, the compound at a dose of 1 mg/kg increased the number of open arm
entries in the EPM test and the time spent in the light area as well as the number of transitions in the
light/dark test.
Zerumin A (207) and coronarin D (208), two labdan-type diterpenes, were isolated from Curcuma
kwangsiensis [151]. The compounds, at a concentration of 300 µM, potentiated GABA-induced chloride
currents in the Xenopus oocyte assay by 309.4 and 211.0%, respectively, with EC50 values of 24.9
and 35.7 µM.
Ginkgolides A (209), B (210) and C (211), diterpene trilactones from Ginkgo biloba, were found to
be moderately potent antagonists at GABA(A) receptors expressed in Xenopus laevis oocytes, with Ki
values of 14.5, 12.7 and 16.3 µM, respectively [152]. IC50 values of the three compounds were 11.9,
10.1 and 12.0 µM, respectively. A study on ginkgolide B and bilobalide (212) using cortical neurons
found the compounds to inhibit chloride currents by 63.2 and 46.8% at a concentration of 50 µM [153].
IC50 values of the compounds were 73 and 76 µM, respectively. A radioligand binding assay of
bilobalide using [35S]TBPS determined a Kd value of 3.7 µM [154]. In the same study the impact on
the flux of 36chloride was measured. Bilobalide, at a concentration of 1000 µM totally blocked chloride
uptake into synaptoneurosomes but showed only low potency with an IC50 value of 39 µM.
As for the sesquiterpenes, only a few findings can be gathered for the diterpenes from the reported
data. One observation relates to the receptor affinity of compounds 200 and 201, which is increased
almost 10-fold by an oxo-group instead of an methoxy-group in position 7. For compounds 203 and
204, one the other hand, the shift of a double bond from position 7 to 8, and thus into ring C of the
compound, doubles the maximal potentiation and markedly reduces the EC50 value. Regarding the
inhibitory acitivity of bilobalide and ginkgolids A-C, no clear differences can be observed in their IC50
values, nor in their ability to block GABA-induced chloride currents.
3.4.4. Triterpenes
The last compound class to be discussed in this review are triterpenes and, most of all, triterpene
glycosides (Figure 14).
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Dipsacus saponin C (213), an oleanol-type triterpenoid isolated from Dipsacus asper, showed
inhibition of tail-flick responses after intrathecal administration of 3.75 to 30 µg of the compound [155].
Pretreatment with 5-aminovaleric (1 to 20 µg i.c.v.) and gabazine (0.1 to 2 ng i.c.v.) both attenuated the
inhibition induced by compound 213.
Julibroside C1 (214) was isolated from Albizia julibrissin and investigated for its anxiolytic
potential [156]. In the EPM test, the compound increased the number of open arm entries and
time spent in open arms at doses of 0.5 and 1 mg/kg p.o., but had no effect on distance travelled.
Flumazenil (10 mg/kg) and bicuculline (3 mg/kg) reduced the time spent in open arms.
Smilaxin B (215), was isolated from Smilax sieboldii and tested in the tail flick response assay,
where it showed an inhibition of tail flick responses at doses from 7.5 to 30 µg i.c.v. [157]. The inhibition
reached a peak at 7.5 min and lasted for 45 min. Muscimol (50 ng i.c.v.) reduced the inhibition induced
by 30 µg smilaxin B.
Platycodin D (216), from Platycodon grandiflorus, also showed antinociceptive properties in the
tail flick response test [158]. Inhibition of tail flick responses were observed at doses from 0.5 to 2 µg
i.c.v., reached a peak at 15 min and lasted for at least 1 h. Muscimol at doses from 50 to 200 ng i.c.v.
antagonized the effect.
β-amyrin (217) was investigated in the pentobarbital induced sleep model by Jeon et al. [159].
The compound exhibited a prolongation of sleep duration at a dose of 10 mg/kg p.o. and decreased
the onset time at doses of 3 and 10 mg/kg p.o. Both effects were reversed by bicuculline (0.3 mg/kg
i.p.). β-amyrin was additionally showed a decrease of locomotor activity in the open field at a dose of
10 mg/kg p.o.
Betulin (218) was analysed in a radioligand binding assay using [3H]GABA and showed a Ki value
of 64 µM [160]. The compound was subsequently analysed for its protection against bicucullin-induced
Molecules 2018, 23, 1512 24 of 44
seizures and found to inhibit the effect of bicuculline at doses of 50 and 100 mg/kg. The protective
effect of betulin was also observed after i.c. injection of 10, 50 or 100 nmole/mice.
Asiatic acid (219) was isolated from Centella asiatica and tested for its anxiolytic potential in
the EPM [161]. The compound had no effect on the percentage of time spent in the open arms but
decreased the time mobile and the maximum speed at doses of 30 mg/kg. Co-application of flumazenil
antagonised both effects.
Ginsenoside C (220), one of several glycosides from Panax ginseng, was tested on GABA(A)
receptors expressed in Xenopus laevis oocytes and found to potentiate GABA-induced chloride currents
with an EC50 value of 53.2 µM [162].
Lee et al. reported lower EC50 values for the two aglycons protopanaxadiol (221) and M4 (222),
which were calculated as 23.1 and 17.1 µM respectively [163]. However, both compounds only
exhibited a weak potentiation of GABA-induced chloride currents.
Ginsenoside Rb1 (223) and Rg1 (224) were investigated for their anxiolytic-like effects in the EPM
test [164]. Both compounds increased the number of open arm entries at doses of 10, 25 and 50 mg/kg
p.o. and time spent in the open arms at 50 mg/kg p.o. Ginsenoside Rb1 additionally increased the
time spent in the open arms at a dose of 25 mg/kg and showed a decrease of locomotor activity at a
dose of 50 mg/kg p.o. In the locomotor activity test.
Ginsenoside Rh2 (225) and Rg3 (226) were also analysed in the EPM test showing an increased
number of open arm entries at doses of 10 and 25 mg/kg p.o. and time spent in the open arms at a
dose of 25 mg/kg p.o. [165]. Ginsenoside Rh2 additionally increased the time spent in the open arms
at a dose of 10 mg/kg p.o.
Ginsenoside Rb3 (227) was investigated for its neuroprotective effect and found the compound
to be acting in a similar way as muscimol [166]. Because both, bicucullin and picrotoxin
prevented neuroprotection, the authors concluded the neuroprotective effects to be mediated via
the GABA(A) receptor.
Four cycloartane glycosides (228–231) were isolated from the rhizomes of Actaea racemosa and
measured for their potentiation of GABA-induced chloride currents in Xenopus laevis oocytes [167].
At a concentration of 300 µM, compounds 228–230 showed a potentiation of GABA-induced chloride
currents in a range from 256 to 378%, while 23-O-acetylshengmanol-3-O-β-D-xylopyranoside (231)
exhibited a stimulation of 1947% and was also found to produce small chloride currents in the
absence of GABA. EC50 values of the four glycosides were calculated from 26 to 36 µM. Interestingly,
cleavage of the pentose moiety led to a significant decrease of activity (especially for compound 231).
Compound 231 was subsequently subjected to several in vivo studies to examine its anxiolytic and
sedative properties [168]. Compound 231 increased the number of open entries at 0.6 mg/kg in the
EPM test and reduced stress-induced hyperthermia at doses of 0.2, 0.6, 2 and 6 mg/kg. In the open
field test the compound reduced the distance travelled at doses of 6, 20 and 60 mg/kg and increased
the time spent in the centre at a dose of 60 mg/kg, while the number of entries into the centre was
reduced. Moreover, the compound was found anticonvulsant in the PTZ-induced seizures model,
elevating the seizure threshold at doses of 20 and 60 mg/kg.
In contrast to the last two subsections, the structure-acitivity discussion of the triterpenes is
not hindered by the lack of comparable structures (scaffolds), but by the number of different test
systems used for their examination. However, at least some of the reported triterpenes from ginseng
(220–222) and black coshosh (228–231) can be compared within and to each other. Electrophysiological
recordings of the three ginseng tritperpenes revealed lower EC50 concentrations for the two aglycons
(221,222) compared to ginsenoside C (220). Alas, values for the maximal potentiation of chloride
currents were only found for the two aglycons and reported to be 54.1 and 23.3%, respectively
(at a concentration of 100 µM). That the receptor modulation of the glycoside would be of great
interest can be concluded after looking at compound 231, where cleavage of the xylose moiety shifted
the potentiation of GABA-induced chloride currents from 1692% to 64% (at 100 µM) and thus into
the range of the ginseng aglycons. When comparing their scaffolds, compound 231 as well as the
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ginsenosides show a four-ring system with a side chain attached to ring D. This side chain reminds
of the structure-activity-relationship of coumarins, where prenylated and oxyprenylated side chains
increased the activity. In the case of the discussed triterpenes, the ginsenoside side-chain would stand
for the prenyl moiety and that of compound 231 for the more potent epoxylated form. However,
compound 231 shows additional features that could contribute to its pronounced effect, like the
keto-function in position 16 or the acetyloxy-group in at C-23, which both distinguish the compound
from the other, markedly less active, cycloartanoids (228–230). Regarding the possible binding site,
the neurosteroid binding site would be most obvious and in line with the fact that neurosteroids are
the most potent natural GABA(A) receptor modulators and are furthermore able to evoke chloride
currents in the absence of GABA [19,169]. However, for the neurosteroid binding site a hydroxy-group
in position 3 and a keto-group in position 17 or 20 are considered essential for the activity [170].
Regarding the structure of compound 231, the keto-group in position 16 instead of position 17 may
well contribute to receptor binding but the fact that the compound’s activity almost disappears with
the xylose moiety, does not support this theory, unless a sugar residue instead of a hydroxy-group
in position 3 would be able to increase binding to the neurosteroid site. On the other hand, also
barbiturates are known to directly activate GABA(A) receptors at higher concentrations and the
barbiturate binding site is hypothesized to be similar to that for neurosteroids [19].
4. Conclusions
A total of 231 natural products with activity on GABA(A) receptors were found in the literature
and discussed in this review. Depending on the number of similar compounds and test systems used,
more or fewer conclusions on their structure-activity relationships were possible. As most studies
investigated flavones, and these studies mainly applied radioligand binding assays, the substitution
patterns responsible for increased receptor affinity could be identified, with one flavone even
showing diazepam-like Ki values. In terms of receptor modulation, flavones were found to be either
non-competitive antagonists or partial agonists. However, some compounds still exhibited anxiolytic
or anticonvulsive effects. Other phenolic compounds discussed in this review were e.g., coumarins,
where prenylated compounds showed higher receptor stimulation. The correlation of prenyl residues
and pronounced receptor modulation was also observed for flavanes, isoflavonoids and chalcones and
might be interesting for the development of GABA(A) receptor modulators.
Moreover, the necessary structural features for the positive or negative receptor modulation of
polyacetylenes and monoterpenes were highlighted, as well as the effect of deglycosylation in the case
of some triterpenes. Regarding subtype-specifity of natural products, only limited reports have been
found. One example is the enhanced receptor modulation of isopimaric and sandaropimaric acid after
exchange of the α1-subunit for α2- or α3-subunits. In this context, the neolignane honokiol must also
be mentioned, although the effect was more dependent on the β-subunits of the GABA(A) receptor.
Here, the collected data of reported in vivo studies might be helpful, as several compounds have been
identified to exhibit anxiolytic effects without showing sedative or muscle relaxant properties.
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Table 1. Data from electrophysiological studies of GABA(A) receptor antagonists.
Cmpd Source Assay Subtype c(GABA) Imax [%] c [µM] IC50 [µM] Ref.
1 Colchicum autumnale Xenopus oocytes α1β2γ2L 10 µM 59.9 ± 6.2 100 [23]
19 Aconitum leucostomum Hippocampal neurons 19.6 [31]
22 Oenanthe fistulosa HEK-293T cells α1β2γ2L 1.39 [35]
23 Oenanthe fistulosa HEK-293T cells α1β2γ2L 0.835 [35]
26 Cicuta virosa Hippocampal neurons 10 µM 90 10 0.96 [37]
34 Xenopus oocytes α1β2γ2S 14.8 ± 0.8 30 [54]
45 Xenopus oocytes α1β2γ2S 12.1 ± 0.5 30 [54]
56 Scuttelaria baicalensis CA1 neurons 10 µM 38.2 ± 6 100 [46]
63 Xenopus oocytes α1β2γ2S 50.6 ± 0.8 30 [54]
63 Matricaria recutita Cerebellar granule cells 10 µM 32 ± 4 10 [55]
63 Xenopus oocytes α1β2γ2L 40 µM 49.6 100 8 [56]
63 Xenopus oocytes α1β2γ2S 6.9 ± 0.3 [57]
64 HEK-293T cells α1β2γ2 66.5 ± 6.8 6.62 ± 2.11 [62]
73 Xenopus oocytes α1β2γ2S 84.5 ± 4.9 30 [54]
74 Xenopus oocytes α1β2γ2S 38.4 ± 4.8 30 [54]
84 Xenopus oocytes α1β2γ2L 40/20 µM 90.6/97 100 14.7/8.7 [56]
96 Xenopus oocytes α1β2γ2L 40/5 µM 51/40 100 29.2/11.7 [56]
134 Xenopus oocytes α1β2γ2L 5.79 [108]
154 Dorsal root ganglia 300 µM 100 30 21 [117]
154 HEK-293T cells α1β2δ 60 300 [118]
197 Illicium anisatum Dorsal root ganglia 30 µM 41.7 1 1.10 ± 1.40 [144]
209 Ginkgo biloba Xenopus oocytes α1β2γ2L 300 µM 11.9 ± 1.7 [152]
210 Ginkgo biloba Xenopus oocytes α1β2γ2L 300 µM 10.1 ± 2.9 [152]
210 Ginkgo biloba Cortical neurons α1β2γ2L 30 µM 63.2 ± 0.3 50 73 [153]
211 Ginkgo biloba Xenopus oocytes α1β2γ2L 300 µM 12.0 ± 2.2 [152]
212 Ginkgo biloba Cortical neurons α1β2γ2L 30 µM 46.8 ± 0.3 50 76 µM [153]
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Table 2. Data from electrophysiological studies of GABA(A) receptor agonists.
Cmpd Source Assay Subtype c(GABA) Pmax [%] c [µM] EC50 [µM] Ref.
5 Piper nigrum Xenopus oocytes α1β2γ2S EC5–10 302 ± 26 300 52 ± 9 [25]
6 Piper nigrum Xenopus oocytes α1β2γ2S EC5–10 187 ± 10 300 56 ± 19 [25]
20 Xenopus oocytes α1β2γ2 1 µM 295 ± 50 300 [33]
31–33 Cussonia zimmermannii Xenopus oocytes α1β2γ2 110–440 0.6–3.5 [40]
46 Scuttelaria baicalensis Xenopus oocytes α1β2γ2 EC1 57 ± 6 30 3 [48]
66 Xenopus oocytes α1β2γ2 EC2–5 47 ± 5 10 [57]
82 Xenopus oocytes α4β4δ 68 ± 5 100 [76]
88 Sophora flavescens Xenopus oocytes α1β2γ2S EC3–10 578.5 ± 68.8 8.1 ± 1.4 [79]
89 Sophora flavescens Xenopus oocytes α1β2γ2S EC3–10 267.6 ± 56.6 5.0 ± 2.3 [79]
90 Sophora flavescens Xenopus oocytes α1β2γ2S EC3–10 604.9 ± 108.2 15.0 ± 3.6 [79]
92 Morus alba Xenopus oocytes α1β2γ2S 730.4 ± 76.7 100 13.8 ± 1.5 [81]
93 Morus alba Xenopus oocytes α1β2γ2S 715.8 ± 56.1 100 16.7 ± 2.0 [81]
94 Morus alba Xenopus oocytes α1β2γ2S 719.3 ± 63.3 100 13.4 ± 1.6 [81]
95 Adenocarpus cinncinatus Xenopus oocytes α1β2γ2S EC5–10 552.73 ± 84.07 500 2.8 ± 1.4 [82]
97 Glycyrrhiza glabra Dorsal raphe neurons α2β2/3γ2L 2 µM 581 ± 91 3 [83]
98 Dorsal raphe neurons EC10 151 10 [84]
99 Sophora flavescens Xenopus oocytes α1β2γ2S EC3–10 891.5 ± 163.0 4.0 ± 2.4 [79]
101 HEK-293T cells α1β2γ2 290 ± 28 [86]
102 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 1200 ± 163 500 171.5 ± 34.6 [87]
103 Magnolia officinalis Xenopus oocytes α1β2γ2S 1315 ± 281 300 36.2 ± 14.7 [88]
106 HEK-293T cells 10.1 ± 10.5 [93]
107 HEK-293T cells 16.9 ± 0.3 [93]
108 HEK-293T cells 10.5 ± 2.3 [93]
109 Cortical neurons 10 µM 158 ± 20 1 0.04258 [94]
110 Piper methysticum Neonatal rat gastric-brainstempreparation 31.5 ± 3.9 300 93 [95]
111 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 218.1 ± 20.8 21.8 ± 7.5 [96]
112 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 245.0 ± 59.6 52.2 ± 24.8 [96]
113 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 885.8 ± 291.2 135.6 ± 85.7 [96]
114 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 168.7 ± 41.5 36.6 ± 16.4 [96]
115 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 129.7 ± 36.8 118.7 ± 54.4 [96]
116 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 395.6 ± 27.2 31.5 ± 7.1 [96]
117 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 288.8 ± 23.7 12.8 ± 3.1 [96]
118 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 793.4 ± 107.4 79.2 ± 19.4 [96]
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Table 2. Cont.
Cmpd Source Assay Subtype c(GABA) Pmax [%] c [µM] EC50 [µM] Ref.
119 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 362.5 ± 87.1 54.6 ± 28.8 [96]
121 Cnidium monnieri Xenopus oocytes α1β2γ2S 54 ± 13 [99]
121 Angelica pubescens Xenopus oocytes α1β2γ2S EC5–10 25.8 ± 12.7 300 [100]
122 Xenopus oocytes α1β2γ2S 57 ± 4 [99]
124 Xenopus oocytes α1β2γ2S 550 ± 71 100 25 ± 8 [99]
125 Xenopus oocytes α1β2γ2S 34 ± 6 [99]
126 Angelica pubescens Xenopus oocytes α1β2γ2S EC5–10 204.5 ± 33.2 300 [89]
127 Cnidium monnieri Xenopus oocytes α1β2γ2S 124 ± 11 100 14 ± 1 [99]
127 Angelica pubescens Xenopus oocytes α1β2γ2S EC5–10 273.6 ± 39.4 300 [100]
128 Angelica pubescens Xenopus oocytes α1β2γ2S EC5–10 61.2 ± 20.2 300 [100]
129 Angelica pubescens Xenopus oocytes α1β2γ2S EC5–10 38.0 ± 21.3 300 [100]
131 Haloxylon scoparium Xenopus oocytes α1β2γ2S 144.6 ± 35.3 500 140.2 ± 51.2 [106]
132 Rhizoma curcumae oil HEK-293T cells α1β2γ2 1 µM 120 ± 6 50 [107]
133 Xenopus oocytes α1β2γ2L EC10 (3 µM) 126 ± 15 100 58.24 [108]
135 Pholidota chinensis Xenopus oocytes α1β2γ2S EC3–10 786.8 ± 72.1 300 175.5 ± 25.5 [109]
136 Pholidota chinensis Xenopus oocytes α1β2γ2S EC3–10 1512.9 ± 176.5 300 52.5 ± 17.0 [109]
137 Adenocarpus cinncinatus Xenopus oocytes α1β2γ2S EC5–10 771.09 ± 57.94 500 40.7 ± 4.08 [82]
138 Adenocarpus cinncinatus Xenopus oocytes α1β2γ2S EC5–10 640.02 ± 53.56 500 8.6 ± 1.6 [82]
139 Adenocarpus cinncinatus Xenopus oocytes α1β2γ2S EC5–10 490.97 ± 22.34 500 18.8 ± 2.3 [82]
140 Juncus effusus Xenopus oocytes α1β2γ2S EC5–10 188 ± 20 300 31 ± 8 [110]
141 Juncus effusus Xenopus oocytes α1β2γ2S EC5–10 239 ± 18 300 27 ± 6 [110]
149 Xenopus oocytes α1β2γ2L EC5–14 1251 ± 73 300 247.7 [115]
150 Xenopus oocytes α1β2γ2L EC15–24 1106 ± 73 300 236.9 [115]
151 Xenopus oocytes α1β2γ2L EC25–39 571 ± 123 300 111.2 [115]
152 Xenopus oocytes α1β2γ2L EC15–24 968 ± 88 300 190.5 [115]
153 Xenopus oocytes α1β2γ2L EC15–24 377 ± 156 300 469.1 [115]
160 Xenopus oocytes α1β3γ2S EC20 416 ± 72 100 [123]
161 Xenopus oocytes α1β2γ2 1 µM 224 ± 85 300 [33]
162 Xenopus oocytes α1β2γ2 1 µM 453 ± 176 300 [33]
163 Xenopus oocytes α1β2γ2 1 µM 340 ± 70 300 [33]
164 Xenopus oocytes α1β2γ2 1 µM 213 ± 105 300 [33]
165 Xenopus oocytes α1β2γ2 1 µM 477 ± 68 300 [33]
166 Xenopus oocytes α1β2γ2 1 µM 809 ± 118 300 [33]
167 HEK-293T cells α1β2γ2 1 µM 156 ± 26 1000 [33]
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Table 2. Cont.
Cmpd Source Assay Subtype c(GABA) Pmax [%] c [µM] EC50 [µM] Ref.
168 HEK-293T cells α1β2γ2 1 µM 168 ± 42 1000 [33]
169 HEK-293T cells α1β2γ2 1 µM 116 ± 56 1000 [33]
170 HEK-293T cells α1β2γ2 1 µM 179 ± 55 1000 [33]
171 Xenopus oocytes α1β2γ2 1 µM 737 ± 234 300 [33]
175 Xenopus oocytes α1β2γ2S EC20 496 ± 113 100 [131]
175 Xenopus oocytes α1β2γ2S EC20 96.2 ± 3.8 50 [132]
176 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 834.6 ± 77.5 70.6 ± 12.2 [96]
177 HEK-293T cells α1β2γ2 1 µM 117 ± 57 1000 [33]
178 HEK-293T cells α1β2γ2 1 µM 115 ± 52 1000 [33]
179 Rhizoma curcumae oil HEK-293T cells α1β2γ2 1 µM 133 ± 10 50 [107]
180 Rhizoma curcumae oil HEK-293T cells α1β2γ2 1 µM 251 ± 16 300 34.4 ± 2.9 [107]
182 Valeriana officinalis Xenopus oocytes α1β2γ2S EC5–10 400.0 ± 77.6 100 13.6 ± 4.1 [135]
183 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 383.5 ± 89.3 57.3 ± 19.7 [96]
184 Kadsura longipedunculata Xenopus oocytes α1β2γ2S EC5–10 413.4 ± 66.3 118.4 ± 29.9 [96]
188 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 241 ± 23.1 500 34.0 ± 6.7 [87]
189 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 669 ± 112 1000 64.8 ± 19.8 [87]
190 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 164 ± 42.9 500 109.4 ± 46.6 [87]
191 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 886 ± 105 1000 135.1 ± 34.4 [87]
192 Acorus calamus Xenopus oocytes α1β2γ2S EC5–10 588 ± 126 300 65.3 ± 21.6 [87]
193 Aristolochia manshuriensis Xenopus oocytes α1β2γ2S EC5–10 70.7 ± 2.6 1000 56.02 ± 5.09 [140]
194 Atractylodes macrocephala Xenopus oocytes α1β2γ2S EC1–10 96 ± 3 300 12 ± 1 [141]
195 Atractylodes macrocephala Xenopus oocytes α1β2γ2S EC1–10 166 ± 122 300 70 ± 17 [141]
196 Atractylodes macrocephala Xenopus oocytes α1β2γ2S EC1–10 157 ± 12 300 99 ± 20 [141]
198 Acremonium strictum Xenopus oocytes α1β1γ2S EC20 180 1 0.05 ± 0.02 [145]
202 Boswellia serrata Xenopus oocytes α1β2γ2S EC5–10 397.5 ± 34.0 100 8.7 ± 1.3 [148]
203 Platycladus orientalis Xenopus oocytes α1β2γ2S EC5–10 425.2 ± 96.5 500 141.6 ± 68.0 [149]
204 Platycladus orientalis Xenopus oocytes α1β2γ2S EC5–10 855.7 ± 114.9 500 33.2 ± 8.7 [149]
207 Curcuma kwangsiensis Xenopus oocytes α1β2γ2S EC3–10 309.4 ± 35.6 300 24.9 ± 8.8 [151]
208 Curcuma kwangsiensis Xenopus oocytes α1β2γ2S EC3–10 211.0 ± 26.0 300 35.7 ± 8.8 [151]
220 Panax ginseng Xenopus oocytes α1β2γ2S 10 µM 53.2 ± 12.3 [162]
221 Panax ginseng Xenopus oocytes α1β2γ2S 10 µM 23.3 ± 1.4 100 23.1 ± 8.6 [163]
222 Panaxginseng Xenopus oocytes α1β2γ2S 10 µM 54.1 ± 1.7 100 17.1 ± 2.2 [163]
228 Actaea racemosa Xenopus oocytes α1β2γ2S EC3–10 378 ± 64 300 36 ± 14 [167]
229 Actaea racemosa Xenopus oocytes α1β2γ2S EC3–10 256 ± 40 300 28 ± 17 [167]
230 Actaea racemosa Xenopus oocytes α1β2γ2S EC3–10 289 ± 45 300 26 ± 7 [167]
231 Actaea racemosa Xenopus oocytes α1β2γ2S EC3–10 1947 ± 185 300 27 ± 8 [167]
Molecules 2018, 23, 1512 30 of 44
Table 3. Data from radioligand binding assays.
Cmpd Source Binding Site Ligand IC50 [µM] Ki [µM]
Stimulation
[%] c [µM] Ref.
4 Leonurus japonicus GABA/muscimol [3H]gabazine 15,000 [24]
19 Aconitum leucostomum GABA/muscimol [3H]muscimol 7.06 [31]
218 GABA/muscimol [3H]GABA 64 ± 5 [160]
2 Colchicum szovitsii benzodiazepine [3H]flunitrazepam
25% of 10 µM
allopregnanolone 10 [22]
3 Colchicum szovitsii benzodiazepine [3H]flunitrazepam
25% of 10 µM
allopregnanolone 10 [22]
4 Leonurus japonicus benzodiazepine [3H]flumazenil 123,000 [24]
16 Oceanapia sp. benzodiazepine [3H]diazepam 39 25 [30]
17 Oceanapia sp. benzodiazepine [3H]diazepam 32 25 [30]
18 Oceanapia sp. benzodiazepine [3H]diazepam 30 25 [30]
34 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 7.81 ± 1.81 [42]
35 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 4.20 ± 0.27 [42]
36 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.21 ± 0.10 [42]
37 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.56 ± 0.07 [42]
38 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.027 ± 0.003 [42]
39 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 6.42 ± 0.95 [41]
40 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.0075 ± 0.004 [42]
41 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.28 ± 0.076 [41]
42 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 2.64 ± 0.36 [42]
43 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.034 ± 0.001 [42]
44 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 9.46 ± 1.45 [42]
45 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.69 ± 0.12 0.64 ± 0.26 [41,42]
46 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 1.26 ± 0.24 1.52 ± 0.13 [41,42]
47 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.36 ± 0.095 0.20 ± 0.05 [41,42]
48 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.008 ± 0.0002 0.0061 ± 0.0001 [41,42]
49 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.31 ± 0.088 [41]
50 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.0038 ± 0.005 [42]
51 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 5.58 ± 0.02 [42]
52 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 21.0 ± 1.79 [41]
53 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 21.4 ± 1.42 [41]
54 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 10.1 ± 1.68 [41]
55 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam >100 [41]
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Table 3. Cont.
Cmpd Source Binding Site Ligand IC50 [µM] Ki [µM]
Stimulation
[%] c [µM] Ref.
56 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 0.14 ± 0.01 0.89 ± 0.06 [41,42]
57 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 22.6 ± 1.30 [41]
58 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 12.5 ± 1.58 [41]
59 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 1.27 ± 0.08 [41]
60 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 6.80 ± 1.18 [41]
61 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 32.8 ± 1.51 [41]
62 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 45.7 ± 2.48 [41]
63 Tanacetum parthenium benzodiazepine [3H]flumazenil 12 9 [60]
63 Salvia officinalis benzodiazepine [3H]flumazenil 30 ± 4 [65]
63 Rhus pyroides benzodiazepine [3H]flumazenil 10.0 ± 1.18 [59]
63 Matricaria recutita benzodiazepine [3H]flunitrazepam 4 [58]
66 Artemisia herba-alba benzodiazepine [3H]flumazenil 8 [66]
66 Salvia officinalis benzodiazepine [3H]flumazenil 1.3 ± 0.2 [65]
67 Salvia officinalis benzodiazepine [3H]flumazenil 350 ± 37 [65]
68 Salvia coerulea benzodiazepine [3H]flunitrazepam 200 [67]
68 Salvia coerulea benzodiazepine [3H]zolpidem 20 [67]
69 Artemisia herba-alba benzodiazepine [3H]flumazenil 100 [66]
70 Artemisia herba-alba benzodiazepine [methyl-3H]DZP 1.3 [68]
71 Artemisia herba-alba benzodiazepine [methyl-3H]DZP 22.7 [68]
78 Hypericum perforatum benzodiazepine [3H]flunitrazepam 0.0149 [74]
78 Searsia pyroides benzodiazepine [3H]flunitrazepam 37 [59]
79 Searsia pyroides benzodiazepine [3H]flunitrazepam 28 [59]
85 Mentha aquatica benzodiazepine [3H]flumazenil 2600 [78]
87 Scuttelaria baicalensis benzodiazepine [3H]flunitrazepam 21.4 ± 1.32 [41]
91 Glycyrrhiza glabra benzodiazepine [3H]flumazenil 1.63 [80]
98 benzodiazepine [3H]flunitrazepam 0.453 [84]
121 Angelica dahurica benzodiazepine [3H]diazepam 8.0 ± 0.8 [98]
122 Angelica dahurica benzodiazepine [3H]diazepam 0.36 ± 0.03 [98]
123 Angelica dahurica benzodiazepine [3H]diazepam 12 ± 3 [98]
154 benzodiazepine [3H]flunitrazepam 74.44 [120]
156 benzodiazepine [3H]flunitrazepam 15.69 [120]
157 benzodiazepine [3H]flunitrazepam 90.02 [120]
160 benzodiazepine [3H]flunitrazepam 130.9 [124]
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Table 3. Cont.
Cmpd Source Binding Site Ligand IC50 [µM] Ki [µM]
Stimulation
[%] c [µM] Ref.
181 Cyperus rotundus benzodiazepine [3H]flunitrazepam 105.0 ± 1.60 [134]
186 Mentha aquatica benzodiazepine [3H]flumazenil 190,000 [78]
199 Salvia miltiorrhiza benzodiazepine [3H]flunitrazepam 0.3 [146]
200 Salvia officinalis benzodiazepine [3H]flumazenil 7.2 ± 0.7 [65]
201 Salvia officinalis benzodiazepine [3H]flumazenil 0.8 ± 0.1 [65]
205 Aloysia virgata benzodiazepine [3H]flumazenil 111 ± 13 [150]
206 Aloysia virgata benzodiazepine [3H]flumazenil 56 ± 19 [150]
2 Colchicum szovitsii TBPS/picrotoxin [35S]TBPS
25% of 10 µM
allopregnanolone 10 [22]
3 Colchicum szovitsii TBPS/picrotoxin [35S]TBPS
25% of 10 µM
allopregnanolone 10 [22]
7 Corydalis cava TBPS/picrotoxin [3H]bicuculline 121 ± 2 0.1 [26]
8 Corydalis cava TBPS/picrotoxin [3H]bicuculline 149 ± 2 0.01 [26]
9 Corydalis cava TBPS/picrotoxin [3H]bicuculline 130 ± 3 0.1 [26]
10 Corydalis cava TBPS/picrotoxin [3H]bicuculline 146 ± 7 0.01 [26]
11 Corydalis cava TBPS/picrotoxin [3H]bicuculline 147 ± 3 0.1 [26]
24 Cicuta virosa TBPS/picrotoxin [3H]EBOB 0.54 ± 0.03 [37]
25 Cicuta virosa TBPS/picrotoxin [3H]EBOB 2.01 ± 0.09 [37]
26 Cicuta virosa TBPS/picrotoxin [3H]EBOB 1.15 ± 0.09 [37]
27 Cicuta virosa TBPS/picrotoxin [3H]EBOB 6.01 ± 0.29 [37]
28 Cicuta virosa TBPS/picrotoxin [3H]EBOB 7.87 ± 0.83 [37]
65 Valeriana jatamansi TBPS/picrotoxin [35S]TBPS 0.50 ± 0.17 [63]
79 Rhus parviflora TBPS/picrotoxin [35S]TBPS 0.149 0.091 [75]
80 Rhus parviflora TBPS/picrotoxin [35S]TBPS 0.073 0.045 [75]
81 Rhus parviflora TBPS/picrotoxin [35S]TBPS 0.455 0.280 [75]
145 Ecklonia cava TBPS/picrotoxin [35S]TBPS 7.180 4.419 [80]
146 Ecklonia cava TBPS/picrotoxin [35S]TBPS 1.739 1.070 [80]
147 Ecklonia cava TBPS/picrotoxin [35S]TBPS 4.991 3.072 [80]
148 Ecklonia cava TBPS/picrotoxin [35S]TBPS 2.422 1.491 [80]
154 TBPS/picrotoxin [35S]TBPS 13 ± 4 [117]
155 TBPS/picrotoxin [35S]TBPS 37 ± 8 [117]
197 Illicium anisatum TBPS/picrotoxin [3H]EBOB 0.43 [144]
212 Ginkgo biloba TBPS/picrotoxin [35S]TBPS 39 [154]
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Table 4. Data from in vivo studies.
Cmpd Anxiety/Stress Sedation Convulsions Myorelaxation Analgesia Ref.
VC FP EPM OF HB LD MB FS TS SIH LMA PIS EIS MES PTZ PTX RR HW TF TI
11 0.5 50 50 [27]
12 5 [28]
13 5 [28]
14 2.5 [28]
15 10 – – – [29]
19 0.25 [32]
21 + + + [34]
45 1 – 3 + – – 25 [50–53]
46 7.5 7.5 – 5 5 – – [48,49]
54 10 + + – [43,44]
55 10 [43]
56 – – – – – [47]
63 0.5 50 30 25 0.6 25 – [55,58,61]
65 1 – [64]
68 2 [67]
72 0.2 – [69]
73 0.5 [70]
75 50 [71]
76 100 [72]
77 2.5 5 5 [73]
80 12.5 [75]
84 5 [77]
86 1 [64]
98 25 [84]
103 20 0.1 [89,90]
105 0.05 [92]
107 3 [93]
109 4 4 [94]
120 5 [97]
121 5 5 5 300 [102,103]
125 5 5 5 [103]
127 259 [101]
130 150 [105]
142 50 [111]
143 300 100 100 100 [112]
144 2.5 2.5 5 [113]
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Table 4. Cont.
Cmpd Anxiety/Stress Sedation Convulsions Myorelaxation Analgesia Ref.
VC FP EPM OF HB LD MB FS TS SIH LMA PIS EIS MES PTZ PTX RR HW TF TI
149 5 50 [116]
158 200 300 200 [121]
159 72.75 [122]
163 25 25 25 25 [125]
171 [126]
172 25 25 25 75 [127,128]
173 25 25 25 25 – [129]
174 400 100 200 [130]
180 100 [107]
182 3 [137]
185 10 [138]
187 + [139]
199 10 – [146]
205 0.3 1 [150]
206 1 0.3 1 [150]
213 + [157]
214 0.5 – [156]
215 + [157]
216 + [158]
217 10 3 [159]
219 30 [161]
223 10 50 [164]
224 10 [164]
225 10 [165]
226 10 [165]
231 0.6 6 0.2 20 [168]
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